Polypeptides for the detection and treatment of coronavirus infections - Patents.com
Patent Information
- Application Number
- JP2023534101
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-04
- Filing Date
- 2021-12-03
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for effective treatments and vaccines against SARS-CoV-2, as existing monoclonal antibodies (mAbs) targeting specific immunogenic proteins like the spike protein have limitations, and the nature and frequency of B cell subsets targeting distinct SARS-CoV-2 antigens, such as nucleoprotein (NP) and open reading frame (ORF) proteins, remain poorly understood.
Characterization of the SARS-CoV-2-specific B cell repertoire in convalescent COVID-19 patients identified monoclonal antibodies against spike, ORF8, and NP proteins, leading to the development of novel antibodies and antigen-binding fragments, polypeptides, and compositions for treating or preventing coronavirus infections, including vaccines and diagnostic methods.
The novel antibodies provide insights into antigen specificity and B cell distribution during SARS-CoV-2 infection, offering potential therapeutic and diagnostic solutions, enhancing treatment and prevention strategies.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 121,384, filed December 4, 2020, which is incorporated by reference herein in its entirety.
[0002] Statements about government support This invention was made with government support under Contract Nos. 75N93019C00062 and 75N93019C00051 awarded by the National Institutes of Health. The government has certain rights in this invention.
[0003] Sequence Listing This application contains a Sequence Listing which has been submitted in ASCII format, which is incorporated herein by reference in its entirety. The ASCII copy, created on November 24, 2021, is named ARCDP0715WO_ST25.txt and is 1,359,473 bytes in size.
[0004] I. FIELD OF THE INVENTION Aspects of the present invention relate to at least the fields of virology and molecular biology. [Background technology]
[0005] II. Background Since the emergence of SARS-CoV-2 in December 2019, the World Health Organization has reported that it has spread to over 200 countries, with the number of infections approaching 64 million and the number of deaths approaching 1.5 million worldwide. Despite this burden, the search to identify effective vaccines, treatments, and protective biomarkers continues. The isolation of human monoclonal antibodies (mAbs) specific for immunogenic SARS-CoV-2 proteins holds immense potential, as these mAbs can be rapidly employed as therapeutic agents, diagnostic reagents, and aid in vaccine optimization. Several independent groups have identified potently neutralizing mAbs against the SARS-CoV-2 spike protein, the primary immunogenic surface glycoprotein.1-7 Despite these advances, no mAbs have been isolated against other immunogenic targets of SARS-CoV-2, including the internal nucleoprotein (NP) and open reading frame (ORF) proteins, which have been suggested to induce antibody responses and immunomodulatory effects in humans. 8-12 Moreover, the nature and frequency of B cell subsets targeting distinct SARS-CoV-2 antigens remains poorly understood and is likely shaped by clinical characteristics such as age and disease severity. 6、13、14 Therefore, there is a need in the art for effective treatments against SARS-CoV-2. Summary of the Invention
[0006] overview To address the need for new treatments, we comprehensively characterized the SARS-CoV-2-specific B cell repertoire in convalescent COVID-19 patients and generated mAbs against the spike, ORF8, and NP proteins. Collectively, our data reveal important insights into the distribution of antigen specificity and B cell subsets during SARS-CoV-2 infection in relation to age, sex, and disease severity. Aspects of the present disclosure relate to novel antibodies and antigen-binding fragments, as well as methods of using these fragments. Further aspects relate to polypeptides comprising the antigen-binding fragments of the present disclosure, and compositions comprising the polypeptides, antibodies, and / or antigen-binding fragments of the present disclosure. Nucleic acids encoding the antibodies or antigen-binding fragments of the present disclosure are also described. The present disclosure also relates to nucleic acids encoding antibody heavy chains, wherein the nucleic acid has at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity to one of SEQ ID NOs: 1621-1710 or 2707-2755. Also described are nucleic acids encoding the antibody light chains of the present disclosure, wherein the nucleic acids have at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity to one of SEQ ID NOs: 1711-1800 or 2756-2804. Further aspects relate to vectors or expression vectors comprising the nucleic acids of the present disclosure, and host cells comprising the polypeptides, nucleic acids, vectors, antibodies, or antigen-binding fragments of the present disclosure. The nucleic acids of the present disclosure can be DNA or RNA.
[0007] Also described are methods for producing cells, including introducing one or more nucleic acids of the present disclosure into cells. In some embodiments, the method further comprises culturing the cells under conditions that allow expression of a polypeptide from the nucleic acid. In some embodiments, the method further comprises isolating the expressed polypeptide. The cells may be further defined as human cells, B cells, T cells, Chinese hamster ovary cells, NS0 mouse myeloma cells, PER.C6 cells, or cells described herein.
[0008] A further aspect of the present disclosure relates to a method for treating or preventing a coronavirus infection in a subject, the method comprising administering to the subject an antibody, antigen-binding fragment, polypeptide, nucleic acid, or host cell of the present disclosure. A still further aspect relates to a method for evaluating a sample from a subject, the method comprising contacting a biological sample, or an extract thereof, from the subject with at least one antibody, antigen-binding fragment, or polypeptide of the present disclosure. Also disclosed is a method for diagnosing SARS-CoV-2 infection in a subject, the method comprising contacting a biological sample, or an extract thereof, from the subject with at least one antibody, antigen-binding fragment, or polypeptide of any one of the present disclosures. In some aspects, the compositions of the present disclosure are formulated as vaccines for treating or preventing coronavirus infection. In some embodiments, the antibodies, antigen-binding fragments, or compositions of the present disclosure are used in vaccines to prevent coronavirus infection in subjects who do not have coronavirus infection. In some embodiments, the antibodies, antigen-binding fragments, or compositions of the present disclosure are used to treat a subject with a coronavirus infection.
[0009] Also described are methods for producing cells, including introducing one or more nucleic acids of the present disclosure into cells. In some aspects, the methods further include culturing the cells under conditions that allow expression of a polypeptide from the nucleic acid. In some aspects, the methods further include isolating the expressed polypeptide. Aspects describe methods for producing polypeptides, including introducing one or more nucleic acids or vectors of the present disclosure into cells and isolating the polypeptide expressed from the nucleic acid. The cells may be further defined as human cells, B cells, T cells, Chinese hamster ovary cells, NS0 mouse myeloma cells, PER.C6 cells, or cells described herein.
[0010] A further aspect of the present disclosure relates to a method for treating or preventing a coronavirus infection in a subject, the method comprising administering to the subject an antibody, antigen-binding fragment, polypeptide, nucleic acid, or host cell of the present disclosure. A still further aspect relates to a method for evaluating a sample from a subject, the method comprising contacting a biological sample, or an extract thereof, from the subject with at least one antibody, antigen-binding fragment, or polypeptide of the present disclosure. Also disclosed is a method for diagnosing SARS-CoV-2 infection in a subject, the method comprising contacting a biological sample, or an extract thereof, from the subject with at least one antibody, antigen-binding fragment, or polypeptide of any one of the present disclosures. In some aspects, a composition of the present disclosure is formulated as a vaccine for treating or preventing a coronavirus infection. In some aspects, an antibody, antigen-binding fragment, or composition of the present disclosure is used in a vaccine to prevent a coronavirus infection in a subject who does not have a coronavirus infection. In some aspects, an antibody, antigen-binding fragment, or composition of the present disclosure is used to treat a subject with a coronavirus infection.
[0011] An aspect of the present disclosure relates to an antibody or antigen-binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 from the heavy chain variable region of an antibody clone in Table 1, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3 from the light chain variable region of the same clone in Table 1.
[0013] A further aspect relates to an antibody or antigen-binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region has 80% or at least 80% sequence identity to HCDR1, HCDR2, and HCDR3 from the heavy chain variable region of an antibody clone of Table 1, or , 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein), or at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity with , 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 1109, 1111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 200, 2010, 2020, 2030, 2040, 2050, 2060, 2070, 2081, 2082, 2090, 2103, 2114, 2115, 2126, 2137, 2148, 2150, 2160, 2170, 2182, 2190, 2203, 2219, 2221, 2230, 2241, 2251, 226 , 99, or 100% (or any derivable range therein), or at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) of sequence identity. HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and / or LCDR3 can be determined from the variable region sequence by methods known in the art.In some aspects, the CDRs are HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and / or LCDR3 as determined by the Chothia method. In some aspects, the CDRs are HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and / or LCDR3 as determined by the Kabat method. In some aspects, the CDRs are HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and / or LCDR3 as determined by the IMGT method.
[0012] An aspect of the present disclosure relates to an antibody or antigen-binding fragment, wherein HCDR1, HCDR2, HCDR2, LCDR1, LCDR2, and LCDR3 each comprise an amino acid sequence having at least 80% sequence identity to HCDR1, HCDR2, HCDR2, LCDR1, LCDR2, and LCDR3 of Table 1, wherein HCDR1, HCDR2, HCDR2, LCDR1, LCDR2, and LCDR3 are from the same antibody clone. In some aspects, HCDR1, HCDR2, HCDR2, LCDR1, LCDR2, and LCDR3 are 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable sequence therein) of HCDR1, HCDR2, HCDR2, LCDR1, LCDR2, and LCDR3 of Table 1, respectively. 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity, wherein HCDR1, HCDR2, HCDR2, LCDR1, LCDR2, and LCDR3 are from the same antibody clone. In some aspects, HCDR1, HCDR2, HCDR2, LCDR1, LCDR2, and LCDR3 each comprise the amino acid sequences of HCDR1, HCDR2, HCDR2, LCDR1, LCDR2, and LCDR3 in Table 1, wherein HCDR1, HCDR2, HCDR2, LCDR1, LCDR2, and LCDR3 are from the same antibody clone.
[0013] An aspect of the disclosure relates to an antibody or antigen-binding fragment comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 that have at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity to HCDR1, LCDR2, and LCDR3 from the heavy chain variable region of an antibody clone of Table 1; and wherein the light chain variable region comprises LCDR1, LCDR2, and LCDR3 from the light chain variable region of the same antibody clone of Table 1. 0, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein), or at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein). 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) of sequence identity. In some aspects, the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 that have 80% or at least 80% sequence identity to HCDR1, HCR2, HCR3 from the heavy chain variable region of an antibody clone in Table 1, and wherein the light chain variable region comprises LCDR1, LCDR2, and LCDR3 that have at least 80% sequence identity to LCDR1, LCDR2, and LCDR3 from the light chain variable region of the same antibody clone in Table 1.In some aspects, the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 having the amino acid sequences of HCDR1, HCDR2, and HCDR3 of a clone in Table 1, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3 having the amino acid sequences of LCDR1, LCDR2, and LCDR3 from the light chain variable region of the same clone in Table 1.
[0014] A polypeptide of the present disclosure may comprise at least two antigen-binding fragments, wherein each antigen-binding fragment is independently selected from the antigen-binding fragments of the present disclosure. In some aspects, the polypeptide is multivalent. In some aspects, the polypeptide is multispecific. In some aspects, the polypeptide is bispecific. In some aspects, the polypeptide comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, antigen-binding regions. Each antigen-binding region may be independently selected from the antigen-binding regions of the present disclosure. In some aspects, the polypeptide may have repeat units of the same antigen binding region, e.g., at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, up to 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 repeat units.
[0015] In some aspects, the heavy chain variable region comprises an amino acid sequence having at least 80% sequence identity to the heavy chain variable region of an antibody clone of Table 1, and / or the light chain variable region comprises an amino acid sequence having at least 80% sequence identity to the light chain variable region of the same antibody clone of Table 1. In some aspects, the heavy chain variable region comprises an amino acid sequence having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable sequence therein) to the heavy chain variable region of the antibody clone of Table 1. or 100% (or any derivable range therein) sequence identity. , and / or the light chain variable region is 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable therein) of the light chain variable region of the same antibody clone in Table 1 In some aspects, the heavy chain variable region comprises an amino acid sequence of the heavy chain variable region of an antibody clone of Table 1, and / or the light chain variable region comprises an amino acid sequence of the same antibody clone of Table 1.In some aspects, the antibody or antigen-binding fragment comprises heavy chain framework regions (HFR) 1, HFR2, HFR3, and HFR4, and light chain framework regions (LFR) 1, LFR2, LFR3, and LFR4, wherein HFR1, HFR2, HFR3, and HFR4 comprise amino acid sequences having at least 80% sequence identity to HFR1, HFR2, HFR3, and HFR4, respectively, of the antibody clones in Table 1, and wherein LFR1, LFR2, LFR3, and LFR4 comprise amino acid sequences having at least 80% sequence identity to LFR1, LFR2, LFR3, and LFR4, respectively, of the same antibody clones in Table 1.In some aspects, the antibody or antigen-binding fragment comprises heavy chain framework regions (HFR) 1, HFR2, HFR3, and HFR4 and light chain framework regions (LFR) 1, LFR2, LFR3, and LFR4, wherein HFR1, HFR2, HFR3, and HFR4 are 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 15 6, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein), or at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity, and LFR1, LFR2, LFR3, and LFR4 are 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein), or an amino acid sequence having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity.In some aspects, HFR1, HFR2, HFR3, and HFR4 comprise the amino acid sequences of HFR1, HFR2, HFR3, and HFR4, respectively, of the antibody clone in Table 1, and LFR1, LFR2, LFR3, and LFR4 comprise the amino acid sequences of LFR1, LFR2, LFR3, and LFR4, respectively, of the same antibody clone in Table 1. In some aspects, the antibody or antigen-binding fragment comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence having at least 70% sequence identity to the heavy chain of the antibody clone in Table 1, and the light chain comprises an amino acid sequence having at least 70% sequence identity to the light chain of the same antibody clone in Table 1.In some aspects, the antibody or antigen-binding fragment comprises a heavy chain and a light chain, wherein the heavy chain is 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or the like relative to the heavy chain of an antibody clone in Table 1. or 100% (or any derivable range therein), or at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein). and the light chain comprises an amino acid sequence having a sequence identity of 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivation therein) to the light chain of the same antibody clone in Table 1. In some aspects, the antibody or antigen-binding fragment comprises an amino acid sequence having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity to the antibody or antigen-binding fragment. In some aspects, the antibody or antigen-binding fragment comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of an antibody clone of Table 1 and the light chain comprises the amino acid sequence of the same antibody clone of Table 1.
[0016] In some aspects, the heavy chain variable region comprises a heavy chain framework region having 80% or at least 80% sequence identity to the heavy chain framework region of the antibody clone of Table 1, and the light chain variable region comprises a light chain framework region having 80% or at least 80% sequence identity to the light chain framework region of the same antibody clone of Table 1. In some aspects, the heavy chain variable region comprises a light chain framework region having 80% or at least 80% sequence identity to the heavy chain framework region of the antibody clone of Table 1. In some aspects, the heavy chain variable region comprises a light chain framework region having 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivative thereof) of the heavy chain framework region of the antibody clone of Table 1. heavy chain framework regions having at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity with the and the light chain variable region comprises 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable therein) of the light chain framework regions of the same antibody clone in Table 1. range), or at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% (or any derivable range therein) sequence identity.
[0017] In some aspects, the heavy chain variable region comprises at least 70% sequence identity to the heavy chain variable region of the antibody clone of Table 1, and the light chain variable region comprises at least 70% sequence identity to the light chain variable region of the same antibody clone of Table 1, wherein the heavy and light chains comprise 100% sequence identity to each of the three heavy chain CDRs and three light chain CDRs from the same antibody clone of Table 1. In some aspects, the heavy chain variable region comprises at least 75% sequence identity to the heavy chain variable region of the antibody clone of Table 1, and the light chain variable region comprises at least 75% sequence identity to the light chain variable region of the same antibody clone of Table 1, wherein the heavy and light chains comprise 100% sequence identity to each of the three heavy chain CDRs and three light chain CDRs from the same antibody clone of Table 1. In some aspects, the heavy chain variable region comprises at least 80% sequence identity to the heavy chain variable region of the antibody clone of Table 1, and the light chain variable region comprises at least 80% sequence identity to the light chain variable region of the same antibody clone of Table 1, wherein the heavy and light chains comprise 100% sequence identity to each of the three heavy chain CDRs and three light chain CDRs from the same antibody clone of Table 1. In some aspects, the heavy chain variable region comprises at least 85% sequence identity to the heavy chain variable region of the antibody clone of Table 1, and the light chain variable region comprises at least 85% sequence identity to the light chain variable region of the same antibody clone of Table 1, wherein the heavy and light chains comprise 100% sequence identity to each of the three heavy chain CDRs and three light chain CDRs from the same antibody clone of Table 1. In some aspects, the heavy chain variable region comprises at least 90% sequence identity to the heavy chain variable region of an antibody clone of Table 1, and the light chain variable region comprises at least 90% sequence identity to the light chain variable region of the same antibody clone of Table 1, wherein the heavy and light chains comprise 100% sequence identity to each of the three heavy chain CDRs and the three light chain CDRs from the same antibody clone of Table 1.In some aspects, the heavy chain variable region comprises at least 95% sequence identity to the heavy chain variable region of an antibody clone of Table 1, and the light chain variable region comprises at least 95% sequence identity to the light chain variable region of the same antibody clone of Table 1, wherein the heavy and light chains comprise 100% sequence identity to each of the three heavy chain CDRs and three light chain CDRs from the same antibody clone of Table 1.
[0018] The antibodies or antigen-binding fragments of the present disclosure can be human, chimeric, or humanized. In some aspects, the antibodies or antigen-binding fragments bind to the spike, NP protein, or ORF8 of SARS-CoV-2 by about 10% or more of the antibody or antigen-binding fragment. -6 nM~about 10 -12 In some aspects, the antibody or antigen-binding fragment binds to the spike, NP protein, or ORF8 of SARS-CoV-2 with a kDa of about 10 pM. -3 , 10 -4 , 10 -5 , 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , 10 -13 , 10 -14 , 10 -15 , 10 -16 , 10 -17 , or 10 -18 kD in μM, nM, or pM (or any derivable range therein), at least 10 -3 , 10 -4 , 10 -5 , 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , 10 -13 , 10 -14 , 10 -15 , 10 -16 , 10 -17 , or 10 -18kD in μM, nM, or pM (or any derivable range therein), or up to 10 -3 , 10 -4 , 10 -5 , 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 , 10 -11 , 10 -12 , 10 -13 , 10 -14 , 10 -15 , 10 -16 , 10 -17 , or 10 -18 In some aspects, the antibody or antigen-binding fragment specifically binds to the receptor binding domain (RBD) of the spike protein of SARS-CoV-2 with kDs of μM, nM, or pM (or any derivable range therein). The antibody may also be defined as a neutralizing antibody. In some aspects, the antibody or antigen-binding fragment is further defined as a human antibody or antigen-binding fragment, a humanized antibody or antigen-binding fragment, a recombinant antibody or antigen-binding fragment, a chimeric antibody or antigen-binding fragment, an antibody or antigen-binding fragment derivative, a veneered antibody or antigen-binding fragment, a diabody, a monoclonal antibody or antigen-binding fragment, a single-domain antibody, or a single-chain antibody. In some aspects, the antigen-binding fragment is further defined as a single-chain variable fragment (scFv), F(ab')2, Fab', Fab, Fv, or rIgG. In some aspects, the antibody, antigen-binding fragment, or polypeptide is operably linked to a detectable label. Detectable labels are described herein.
[0019] Aspects of the present disclosure also relate to multispecific and / or multivalent antibodies and polypeptides. Thus, aspects relate to bivalent or bispecific antibodies comprising two antigen-binding fragments, wherein the antigen-binding fragments are two of the same antigen-binding fragment or two different antigen-binding fragments as described herein. The present disclosure also provides multispecific polypeptides. Aspects relate to polypeptides comprising two, three, four, five, or six, or at least two, three, four, five, or six, antigen-binding fragments.
[0020] The antigen-binding fragment may be at least two, three, four, five, or six scFv, F(ab')2, Fab', Fab, Fv, or rIgG, or a combination thereof. The polypeptides and / or antigen-binding fragments of the present disclosure may include a linker between the heavy and light chain variable regions or between the antigen-binding fragments. The linker may be a flexible linker. Exemplary flexible linkers include glycine polymers (G)n, glycine-serine polymers (e.g., (GS)n, (GSGGS-SEQ ID NO:2805)n, (GS)n, and (GGGS-SEQ ID NO:2806)n, where n is an integer of at least 1). In some aspects, n is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (or any derivable range therein), at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (or any derivable range therein), or exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (or any derivable range therein). Glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art can be used as linkers in the polypeptides of the present disclosure. Exemplary linkers can include or consist of GGSG (SEQ ID NO:2807), GGSGG (SEQ ID NO:2808), GSGSG (SEQ ID NO:2809), GSGGG (SEQ ID NO:2810), GGGSG (SEQ ID NO:2811), GSSSG (SEQ ID NO:2812), etc.
[0021] In some aspects, the coronavirus infection is a SARS-CoV-2 infection. In some aspects, the coronavirus infection is a SARS-CoV infection. In some aspects, the coronavirus infection is a MERS-CoV infection. In some aspects, the coronavirus infection is an HCoV-OC43, HCoV-HKU1, HCoV-229E, or HCoV-NL63 infection.
[0022] The compositions of the present disclosure, for example, pharmaceutical compositions, can include pharmaceutical excipients, carriers, or molecules described herein.In some aspects, the compositions further include adjuvants or immunostimulants.Such adjuvants or immunostimulants include stimulators of pattern recognition receptors, such as Toll-like receptors, RIG-1, and NOD-like receptors (NLRs), inorganic salts, such as alum, monophosphoryl lipid (MPL) A of enterobacteria, such as Escherichia coli, Salmonella minnesota, Salmonella typhimurium, or Shigella flexneri, or specifically alum combined with MPL(ASO4), MPL A of the aforementioned bacteria alone, saponins, such as QS-21, Quil-A, ISCOM, ISCOMATRIX, emulsions, such as MF59, Montanide, ISA 51, and ISA 720, AS02 (QS21 + squalene + MPL), liposomes and liposomal formulations such as AS01, synthetic or specially prepared microparticles and microcarriers such as outer membrane vesicles (OMVs) from N. gonorrhea, Chlamydia trachomatis, other bacteria, or chitosan particles, depot-forming agents such as Pluronic block copolymers, specially modified or prepared peptides such as muramyl dipeptide, aminoalkyl glucosaminide 4-phosphate, e.g., RC529, or proteins such as bacterial toxoids or toxin fragments. The compositions may contain more than one antibody and / or antigen-binding fragment of the present disclosure. Thus, a composition of the disclosure can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or at most 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 antibodies and / or antigen-binding fragments of the disclosure. Compositions of the disclosure may be formulated for routes of administration described herein.In some aspects, the composition, antibody, antigen-binding fragment, or polypeptide is formulated for parenteral, intravenous, subcutaneous, intramuscular, or intranasal administration, hi certain aspects, the composition is formulated for intranasal administration.
[0023] In some aspects, the host cell is a human cell, a B cell, a T cell, a Chinese hamster ovary, an NS0 mouse myeloma cell, or a PER.C6 cell. In some aspects, the host cell is a cell type or cell population described herein.
[0024] In aspects of the present disclosure, the subject or patient may be a human subject or patient. In some aspects, the subject or patient is a non-human animal. In some aspects, the non-human animal is a bat, monkey, camel, rat, mouse, rabbit, goat, chicken, bird, cat, or dog. The subject may be further defined as an at-risk subject. At-risk subjects include healthcare workers, immunocompromised subjects, subjects over 65 years of age, or subjects with at least one or at least two underlying conditions. Examples of underlying conditions include obesity, hypertension, autoimmunity, cancer, and asthma. In some aspects, the subject has one or more symptoms of coronavirus infection. Symptoms of coronavirus infection include, but are not limited to, elevated body temperature or fever of 100.0°F or greater, loss of taste or smell, cough, difficulty breathing, shortness of breath, fatigue, headache, chills, sore throat, congestion or runny nose, shivering or excessive shivering, noticeable muscle pain or soreness, diarrhea, and / or nausea or vomiting. In some aspects, the subject does not have any symptoms of coronavirus infection. In some aspects, the subject has been diagnosed with a coronavirus infection. In some aspects, the subject has not been diagnosed with a coronavirus infection. In some aspects, the subject has been previously treated for a coronavirus infection. In some aspects, the subject has been previously vaccinated against a coronavirus. In some aspects, the subject has not been previously vaccinated against a coronavirus. In some aspects, previous treatment comprises analgesics such as acetaminophen or ibuprofen, steroids such as dexamethasone, prednisolone, beclomethasone, fluticasone or methylprednisone, or antiviral drugs such as remdesivir.In some aspects, additional treatment is administered to the subject.Additional treatment can comprise one or more of analgesics such as acetaminophen or ibuprofen, steroids such as dexamethasone, prednisolone, beclomethasone, fluticasone or methylprednisone, or antiviral drugs such as remdesivir.In some aspects, additional treatment comprises dexamethasone.In some aspects, the additional therapy includes remdesivir.
[0025] In some aspects of the present disclosure, the method further includes incubating the antibody, antigen-binding fragment, or polypeptide under conditions that allow binding of the antibody, antigen-binding fragment, or polypeptide to an antigen in the biological sample or an extract thereof. In some aspects, the method further includes detecting binding of the antigen to the antibody, antigen-binding fragment, or polypeptide. In some aspects, the method further includes contacting the biological sample with at least one capture antibody, antigen, or polypeptide. The at least one capture antibody, antigen-binding fragment, or polypeptide can be an antibody, polypeptide, or antigen-binding fragment of the present disclosure. In some aspects, the capture antibody is linked or operably linked to a solid support. The term "operably linked" refers to a situation in which two components are combined or can be combined to form a complex. For example, the components may be covalently linked, e.g., in a fusion protein, and / or on the same polypeptide, or the components may have some degree of binding affinity for each other, e.g., due to van der Waals forces. In some aspects, the biological sample includes a blood sample, a urine sample, a stool sample, or a nasopharyngeal sample. In some aspects of the present disclosure, at least one antibody, antigen-binding fragment, or polypeptide may be functionally linked to a detectable label. In some aspects, the method further comprises incubating the antibody, antigen-binding fragment, or polypeptide under conditions that allow the antibody, antigen-binding fragment, or polypeptide to bind to an antigen in a biological sample or an extract thereof. In some aspects, the method further comprises detecting binding between the antigen and the antibody, antigen-binding fragment, or polypeptide. In some aspects, the method further comprises contacting the biological sample with at least one capture antibody, antigen, or polypeptide. In some aspects, the biological sample comprises a blood sample, a urine sample, a stool sample, or a nasopharyngeal sample.
[0026] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:3-5, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:12-14, respectively.
[0027] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:21-23, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:30-32, respectively.
[0028] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 39-41, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 48-50, respectively.
[0029] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:57-59, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:66-68, respectively.
[0030] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:75-77, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:84-86, respectively.
[0031] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:93-95, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:102-104, respectively.
[0032] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:111-113, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:120-122, respectively.
[0033] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:129-131, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:138-140, respectively.
[0034] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:147-149, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:156-158, respectively.
[0035] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:165-167, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:174-176, respectively.
[0036] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:183-185, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:192-194, respectively.
[0037] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:201-203, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:210-212, respectively.
[0038] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:219-221, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:228-230, respectively.
[0039] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:237-239, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:246-248, respectively.
[0040] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:255-257, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:264-266, respectively.
[0041] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:273-275, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:282-284, respectively.
[0042] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:291-293, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:300-302, respectively.
[0043] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:309-311, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:318-320, respectively.
[0044] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 327-329, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 336-338, respectively.
[0045] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:345-347, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:354-356, respectively.
[0046] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:363-365, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:372-374, respectively.
[0047] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:381-383, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:390-392, respectively.
[0048] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:399-401, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:408-410, respectively.
[0049] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:417-419, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:426-428, respectively.
[0050] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:435-437, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:444-446, respectively.
[0051] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:453-455, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:462-464, respectively.
[0052] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:471-473, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:480-482, respectively.
[0053] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:489-491, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:498-500, respectively.
[0054] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:507-509, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:516-518, respectively.
[0055] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:525-527, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:534-536, respectively.
[0056] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:543-545, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:552-554, respectively.
[0057] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:561-563, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:570-572, respectively.
[0058] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:579-581, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:588-590, respectively.
[0059] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:597-599, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:606-608, respectively.
[0060] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:615-617, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:624-626, respectively.
[0061] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 633-635, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 642-644, respectively.
[0062] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 651-653, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 660-662, respectively.
[0063] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:669-671, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:678-680, respectively.
[0064] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:687-689, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:696-698, respectively.
[0065] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:705-707, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:714-716, respectively.
[0066] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:723-725, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:732-734, respectively.
[0067] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:741-743, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:750-752, respectively.
[0068] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:759-761, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:768-770, respectively.
[0069] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:777-779, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:786-788, respectively.
[0070] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:795-797, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:804-806, respectively.
[0071] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:813-815, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:822-824, respectively.
[0072] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:831-833, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:840-842, respectively.
[0073] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:849-851, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:858-860, respectively.
[0074] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:867-869, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:876-878, respectively.
[0075] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:885-887, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:894-896, respectively.
[0076] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:903-905, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:912-914, respectively.
[0077] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:921-923, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:930-932, respectively.
[0078] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:939-941, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:948-950, respectively.
[0079] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:957-959, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:966-968, respectively.
[0080] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:975-977, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:984-986, respectively.
[0081] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:993-995, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1002-1004, respectively.
[0082] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1011-1013, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1020-1022, respectively.
[0083] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1029-1031, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1038-1040, respectively.
[0084] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1047-1049, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1056-1058, respectively.
[0085] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1065-1067, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1074-1076, respectively.
[0086] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1083-1085, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1092-1094, respectively.
[0087] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1101-1103, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1110-1112, respectively.
[0088] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1119-1121, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1128-1130, respectively.
[0089] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1137-1139, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1146-1148, respectively.
[0090] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1155-1157, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1164-1166, respectively.
[0091] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1173-1175, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1182-1184, respectively.
[0092] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1191-1193, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1200-1202, respectively.
[0093] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1209-1211, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1218-1220, respectively.
[0094] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1227-1229, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1236-1238, respectively.
[0095] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1245-1247, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1254-1256, respectively.
[0096] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1263-1265, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1272-1274, respectively.
[0097] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1281-1283, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1290-1292, respectively.
[0098] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1299-1301, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1308-1310, respectively.
[0099] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1317-1319, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1326-1328, respectively.
[0100] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1335-1337, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1344-1346, respectively.
[0101] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1353-1355, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1362-1364, respectively.
[0102] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1371-1373, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1380-1382, respectively.
[0103] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1389-1391, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1398-1400, respectively.
[0104] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1407-1409, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1416-1418, respectively.
[0105] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1425-1427, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1434-1436, respectively.
[0106] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1443-1445, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1452-1454, respectively.
[0107] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1461-1463, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1470-1472, respectively.
[0108] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1479-1481, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1488-1490, respectively.
[0109] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1497-1499, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1506-1508, respectively.
[0110] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1515-1517, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1524-1526, respectively.
[0111] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1533-1535, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1542-1544, respectively.
[0112] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1551-1553, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1560-1562, respectively.
[0113] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1569-1571, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1578-1580, respectively.
[0114] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1587-1589, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1596-1598, respectively.
[0115] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1605-1607, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1614-1616, respectively.
[0116] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1827-1829, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1836-1838, respectively.
[0117] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1845-1847, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1854-1856, respectively.
[0118] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1863-1865, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1872-1874, respectively.
[0119] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1881-1883, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1890-1892, respectively.
[0120] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1899-1901, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1908-1910, respectively.
[0121] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1917-1919, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1926-1928, respectively.
[0122] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1935-1937, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1944-1946, respectively.
[0123] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1953-1955, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1962-1964, respectively.
[0124] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:1971-1973, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:1980-1982, respectively.
[0125] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 each comprise the amino acid sequence of SEQ ID NO:1989-1991, and LCDR1, LCDR2, and LCDR3 each comprise the amino acid sequence of SEQ ID NO:1998-2000.
[0126] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2007-2009, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2016-2018, respectively.
[0127] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2025-2027, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2034-2036, respectively.
[0128] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2043-2045, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2052-2054, respectively.
[0129] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2061-2063, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2070-2072, respectively.
[0130] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2079-2081, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2088-2090, respectively.
[0131] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2097-2099, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2106-2108, respectively.
[0132] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2115-2117, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2124-2126, respectively.
[0133] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2133-2135, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2142-2144, respectively.
[0134] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2151-2153, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2160-2162, respectively.
[0135] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2169-2171, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2178-2180, respectively.
[0136] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2187-2189, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2196-2198, respectively.
[0137] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2205-2207, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2214-2216, respectively.
[0138] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2223-2225, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2232-2234, respectively.
[0139] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2241-2243, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2250-2252, respectively.
[0140] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2259-2261, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2268-2270, respectively.
[0141] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2277-2279, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2286-2288, respectively.
[0142] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2295-2297, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2304-2306, respectively.
[0143] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2313-2315, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2322-2324, respectively.
[0144] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2331-2333, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2340-2342, respectively.
[0145] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2349-2351, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2358-2360, respectively.
[0146] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2367-2369, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2376-2378, respectively.
[0147] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2385-2387, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2394-2396, respectively.
[0148] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2403-2405, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2412-2414, respectively.
[0149] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2421-2423, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2430-2432, respectively.
[0150] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2439-2441, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2448-2450, respectively.
[0151] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2457-2459, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2466-2468, respectively.
[0152] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2475-2477, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2484-2486, respectively.
[0153] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2493-2495, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2502-2504, respectively.
[0154] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2511-2513, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2520-2522, respectively.
[0155] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2529-2531, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2538-2540, respectively.
[0156] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2547-2549, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2556-2558, respectively.
[0157] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2565-2567, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2574-2576, respectively.
[0158] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2583-2585, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2592-2594, respectively.
[0159] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2601-2603, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2610-2612, respectively.
[0160] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2619-2621, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2628-2630, respectively.
[0161] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2637-2639, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2646-2648, respectively.
[0162] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2655-2657, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2664-2666, respectively.
[0163] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2673-2675, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2682-2684, respectively.
[0164] An aspect of the present disclosure relates to an antibody, antigen-binding fragment, or polypeptide comprising a heavy chain variable region having HCDR1, HCDR2, and HCDR3, and a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs:2691-2693, respectively, and LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs:2700-2702, respectively.
[0165] Aspects of the present disclosure include SEQ ID NOs: 2 and 11, SEQ ID NOs: 20 and 29, SEQ ID NOs: 38 and 47, SEQ ID NOs: 56 and 65, SEQ ID NOs: 74 and 83, SEQ ID NOs: 92 and 101, SEQ ID NOs: 110 and 119, SEQ ID NOs: 128 and 137, SEQ ID NOs: 146 and 155, SEQ ID NOs: 164 and 173, SEQ ID NOs: 182 and 191, SEQ ID NOs: 200 and 209, SEQ ID NOs: 218 and 227, SEQ ID NOs: 236 and 245, SEQ ID NOs: 254 and 263, SEQ ID NOs: 272 and 281, SEQ ID NOs: 290 and 299, SEQ ID NOs: 308 and 317, SEQ ID NOs: 326 and 335, SEQ IDs: NO:344 and 353, SEQ ID NO:362 and 371, SEQ ID NO:380 and 389, SEQ ID NO:398 and 407, SEQ ID NO:416 and 425, SEQ ID NO:434 and 443, SEQ ID NO:452 and 461, SEQ ID NO:470 and 479, SEQ ID NO:488 and 497, SEQ ID NO:506 and 515, SEQ ID NO:524 and 533, SEQ ID NO:542 and 551, SEQ ID NO:560 and 569, SEQ ID NO:578 and 587, SEQ ID NO:596 and 605, SEQ ID NO:614 and 623, SEQ ID NO:632 and 641, SEQ ID NO:650 and 659, SEQ ID NO:668 and 677, SEQ ID NO:686 and 695, SEQ ID NO:704 and 713, SEQ ID NO:722 and 731, SEQ ID NO:740 and 749, SEQ ID NO:758 and 767, SEQ ID NO:776 and 785, SEQ ID NO:794 and 803, SEQ ID NO:812 and 821, SEQ ID NO:830 and 839, SEQ ID NO:848 and 857, SEQ ID NO:866 and 875, SEQ ID NO:884 and 893, SEQID NOs:902 and 911, SEQ ID NOs:920 and 929, SEQ ID NOs:938 and 947, SEQ ID NOs:956 and 965, SEQ ID NOs:974 and 983, SEQ ID NOs:992 and 1001, SEQ ID NOs:1010 and 1019, SEQ ID NOs:1028 and 1037, SEQ ID NOs:1046 and 1055, SEQ ID NOs:1064 and 1073, SEQ ID NOs:1082 and 1091, SEQ ID NOs:1100 and 1109, SEQ ID NOs:1118 and 1127, SEQ ID NOs:1136 and 1145, SEQ ID NOs:1154 and 1163, SEQ ID NOs:1172 and 1181, SEQ ID NOs:1190 and 1199, SEQ ID NO:1208 and 1217, SEQ ID NO:1226 and 1235, SEQ ID NO:1244 and 1253, SEQ ID NO:1262 and 1271, SEQ ID NO:1280 and 1289, SEQ ID NO:1298 and 1307, SEQ ID NO:1316 and 1325, SEQ ID NO:1334 and 1343, SEQ ID NO:1352 and 1361, SEQ ID NO:1370 and 1379, SEQ ID NO:1388 and 1397, SEQ ID NO:1406 and 1415, SEQ ID NO:1424 and 1433, SEQ ID NO:1442 and 1451, SEQ ID NO:1460 and 1469, SEQ ID NO:1478 and 1487, SEQ ID NO:1496 and 1505, SEQ ID NO:1514 and 1523, SEQ ID NO:1532 and 1541, SEQ ID NO:1550 and 1559, SEQ ID NO:1568 and 1577, SEQ ID NO:1586 and 1595, SEQ ID NO:1604 and 1613, SEQ ID NO:1826 and 1835, SEQ ID NO:1844 and 1853, SEQ ID NO:1862 and 1871, SEQ ID NO:1880 and 1889, SEQ ID NO:1898 and 1907, SEQ ID NO:1916 and 1925, SEQID NOs: 1934 and 1943, SEQ ID NOs: 1952 and 1961, SEQ ID NOs: 1970 and 1979, SEQ ID NOs: 1988 and 1997, SEQ ID NOs: 2006 and 2015, SEQ ID NOs: 2024 and 2033, SEQ ID NOs: 2042 and 2051, SEQ ID NOs: 2060 and 2069, SEQ ID NOs: 2078 and 2087, SEQ ID NOs: 2096 and 2105, SEQ ID NOs: 2114 and 2123, SEQ ID NOs: 2132 and 2141, SEQ ID NOs: 2150 and 2159, SEQ ID NOs: 2168 and 2177, SEQ ID NOs: 2186 and 2195, SEQ ID NOs: 2204 and 2213, SEQ ID NO:2222 and 2231, SEQ ID NO:2240 and 2249, SEQ ID NO:2258 and 2267, SEQ ID NO:2276 and 2285, SEQ ID NO:2294 and 2303, SEQ ID NO:2312 and 2321, SEQ ID NO:2330 and 2339, SEQ ID NO:2348 and 2357, SEQ ID NO:2366 and 2375, SEQ ID NO:2384 and 2393, SEQ ID NO:2402 and 2411, SEQ ID NO:2420 and 2429, SEQ ID NO:2438 and 2447, SEQ ID NO:2456 and 2465, SEQ ID NO:2474 and 2483, SEQ ID NO:2492 and 2501, SEQ ID and SEQ ID NOs:2610 and 2619, SEQ ID NOs:2528 and 2537, SEQ ID NOs:2546 and 2555, SEQ ID NOs:2564 and 2573, SEQ ID NOs:2582 and 2591, SEQ ID NOs:2600 and 2609, SEQ ID NOs:2618 and 2627, SEQ ID NOs:2636 and 2645, SEQ ID NOs:2654 and 2663, SEQ ID NOs:2672 and 2681, or SEQ ID NOs:2690 and 2699.
[0166] Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for any measuring or quantitating method.
[0167] The use of the words "a" or "an" when used in conjunction with the term "comprising" may mean "one," but is also consistent with the meanings of "one or more," "at least one," and "one or more than one."
[0168] The phrase "and / or" means "and" or "or." Explained, A, B, and / or C includes A only, B only, C only, A and B in combination, A and C in combination, B and C in combination, or A, B, and C in combination. In other words, "and / or" functions as an inclusive "or."
[0169] The words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include"), or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
[0170] Compositions and methods for their use can "comprise," "consist essentially of," or "consist of" any of the components or steps disclosed throughout this specification. Compositions and methods "consisting essentially of" any of the disclosed components or steps limit the scope of the claims to particular materials or steps that do not materially affect the basic and novel characteristics of the claimed invention. As used in the specification and claims, the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include") or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that embodiments described herein in conjunction with the term "comprising" may also be practiced in conjunction with the term "consisting of" or "consisting essentially of."
[0171] "Individual," "subject," and "patient" are used interchangeably and can refer to a human or non-human.
[0172] It is specifically contemplated that any limitation stated with respect to one embodiment of the invention may apply to any other embodiment of the invention. Furthermore, any composition of the invention may be used in any method of the invention, and any method of the invention may be used to produce or utilize any composition of the invention. Aspects of an embodiment shown in an example are also embodiments that can be practiced in conjunction with embodiments described elsewhere in another example or elsewhere in this application, e.g., in the Summary of the Invention, Detailed Description of the Embodiments, Claims, and Figure Legends.
[0173] Any method related to a therapeutic, diagnostic, or physiological purpose or effect may also be described in "use" claim language, such as "use of" any compound, composition, or agent described herein to achieve or carry out the described therapeutic, diagnostic, or physiological purpose or effect.
[0174] Other objects, features, and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and specific examples, while indicating specific embodiments of the present invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description. [Brief explanation of the drawings]
[0175] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0176] [Figure 1-1]Figure 1a-g. SARS-CoV-2-reactive B cell subsets are revealed by transcriptome, Ig repertoire, and probe binding. a, Model demonstrating antigen probe preparation and a representative gating strategy for sorting antigen-positive B cells. b, Percentages of antigen-probe-positive total B cells (CD19+CD3-), naive B cells (CD27+CD37int), and memory B cells (CD27+CD38int) (left), as well as naive vs. memory B cells per subject (right; n = 17 subjects providing quality sequencing data). Statistics are paired nonparametric Friedman tests (*p = 0.0491; ****p < 0.0001; bars = median). c, Integrated transcriptional UMAP analysis of distinct B cell clusters and corresponding B cell counts by cluster. d, Feature library enrichment of antigen-probe-positive B cells by cluster. e, Probe reactivity rate of total B cells by cluster. f, Ig isotype usage and VH gene SHM for all antigen-positive B cells by cluster. Bars indicate median with interquartile range. g, Representative visualization of antigen reactivity revealing antigen-specific B cells. Axis indicates antigen probe intensity. [Figure 1-2] Please refer to the description of Figure 1-1. [Figure 2-1]Figure 2a-d. Transcriptional analysis identifies naive, innate-like, and MBC subsets specific to SARS-CoV-2 proteins. a-b, Trajectory (a) and pseudotime (b) analysis of clusters 0-11 reveal minimal-maximal differentiation clusters. Cluster 12 is excluded from trajectory analysis because it is a separate compartment defined by Monocle3. c, Heatmap showing the top 20 most differentially expressed genes by cluster. Red stars represent genes used to identify memory B cells (MBCs). d, Volcano plot comparing differentially expressed genes in the MBC-like cluster compared to cluster 2 (naive B cells). Genes used to identify MBCs are shown: cd27, cd38, hhex, zeb2, pou2af1, spib, cd80, cd86, mcl1, prdm1, abp1, manf, bach2, and pax5. Red dots represent log fold changes in expression >0.1 and adjusted p-values <0.01, highlighting clearly defined putative B cell subsets (a). [Figure 2-2] See the description of Figure 2-1. [Figure 3-1] Figure 3a-p. SARS-CoV-2-reactive B cells display unique signatures for isotype, SHM, subset of origin, and VH gene usage. a-l, Distribution of Ig isotype, VH gene SHM, and B cells by cluster incorporated for spike-specific (a, b, c, d), NP-specific (e, f, g, h), and ORF8-specific B cells (i, j, k, l). m-p, Treemaps showing VH gene locus usage frequency for total spike (including RBD) (m), RBD only (n), NP-specific (o), and ORF8-specific B cells (p). Numbers in the center of each pie chart and below each treemap indicate the number of cells / reactivity analyzed. [Figure 3-2] See the description of Figure 3-1. [Figure 4-1]Figure 4a-d. Characterization of mAbs from single SARS-CoV-2-reactive B cells. a) Cluster origin of cloned mAbs (n = 90). b) Representative plot showing the selection of B cells chosen for cloning mAbs. Antigen-binding curves by ELISA for each reactive mAb (Spike, n = 38; RBD, n = 36; NP, n = 19; ORF8, n = 24) and the percentage of total cloned mAbs showing specificity (right). The dashed line on the ELISA curves represents an OD405 cutoff of 0.5 for positivity. c) Neutralization potency (log10 PFU / ml) of mAbs (n = 80) tested by live SARS-CoV-2 virus plaque assay. The dashed line at x = 6.5 indicates the cutoff for neutralization. d) Percentage of total spike-, NP-, and ORF8-specific mAbs that showed neutralizing activity. The numbers below each bar graph indicate the number of mAbs tested for neutralization. ELISA data are representative of two to four independent experiments performed in duplicate, and mAbs were screened once for neutralizing capacity. [Figure 4-2] See the description of Figure 4-1. [Figure 5-1]Figure 5a-i. Correlating B cell antigen targeting, subset distribution, and fitness with clinical features. a) Total serum anti-Ig endpoint titers against SARS-CoV-2 antigens determined by ELISA (n = 25 subjects). b) Number of IgG / IgA antibody-secreting cells (ASCs) / 106 cells determined by ELISpot (n = 23 subjects). c) Percentage of antigen-probe-positive cells per subject. d) Percentage of antigen-probe-positive cells stratified by age (years), sex, and symptom duration (weeks). e) Two-tailed Spearman correlation between the percentage of total cells specific for ORF8 and subject age. p and r values are shown. f) Percentage of antigen-probe-positive B cells in MBC-like clusters (3, 4, 5, 6, 7, 9, and 12) or naive- and spontaneous-like clusters (0, 1, 2, 8, 10, and 11) stratified by age, sex, and symptom duration. (g-i) VH gene SHM for antigen-specific cells from a given age (g), gender (h), or symptom duration group (i). Data in a and b were analyzed using a paired, nonparametric Friedman test with multiple comparisons to spike (*p=0.0154, ****p<0.0001; bars=median). The red dashed line at y=45 in a indicates the cutoff for undetectable serum titers. Data in d and f were analyzed using a two-sided chi-square or Fisher exact test (****p<0.0001; ***p=0.0009). Data in g were analyzed using an unpaired, nonparametric Kruskal-Wallis test with multiple comparisons (****p<0.0001; ***p=0.0002; bars=mean). The statistic used in h and i is an unpaired, nonparametric, two-sided Mann-Whitney test (****p<0.0001; bars=mean). The numbers below each bar graph indicate the number of cells analyzed. [Figure 5-2] See the description of Figure 5-1. [Figure 6A] Further characterization of B cells comprising the integrated clusters. a, Distribution of antigen-probe positive B cells across integrated clusters per subject. Number of cells / subject is shown. [Figure 6B]Further characteristics of B cells containing integrated clusters. b, Variable gene segment utilization in the B cell receptor heavy chain of antigen-probe positive B cells across integrated clusters. [Figure 6C] Further characterization of B cells, including integrated clusters. c, Diagram showing antigen-probe positive B cells / clusters. Probe intensity for the indicated antigens is plotted on the axes. [Figure 7] Expression of MBC and LLPC gene markers in the integrated clusters. Normalized expression levels of the indicated genes are displayed as violin plots. [Figure 8-1] Figure 8a-i. Heavy and light chain characteristics of SARS-CoV-2-reactive B cells. a-b, Heavy chain (HC, a) and light chain (LC, b) complementarity-determining region 3 (CDR3) lengths as indicated by antigen reactivity. c-d, Isoelectric points (pI) of HC (c) and LC (d) as indicated by antigen reactivity. e, Number of light chain (LC) somatic hypermutations (SHM) as indicated by antigen reactivity. f-i. Treemap showing frequency of Vk / L locus usage for spike-specific (f), RBD-specific (g), NP-specific (h), and ORF8-specific B cells (i). Open boxes indicate unique Vk / L usage. In panels a-e, groups were compared by unpaired, nonparametric Kruskal-Wallis test with multiple comparisons (NS = not significant, ****p<0.0001; ***p=0.0006; **p=0.0033). For all analyses shown, n=531 cells were selected for spike, n=47 for RBD, n=293 for NP, and n=463 for ORF8. [Figure 8-2] See the description of Figure 8-1. [Figure 9]Figure 9a-g. Additional characterization of mAbs cloned from antigen-specific and multi-probe-binding B cells. a, ELISA KDs for specific mAbs against spike (n = 38), RBD (n = 36), ORF8 (n = 24), and NP (n = 19) are shown against normalized probe intensities for spike, ORF8, and NP, respectively. Total spike antigen probe intensity is plotted for RBD-binding mAbs. Statistics are two-tailed Spearman correlations, with p and r values shown. b, Example selection of multi-probe-reactive B cells. c, Isotype frequency of multi-probe-reactive B cells. d, Number of VH gene SHMs for multi-probe-reactive B cells. e, Proportion of multi-probe-reactive B cells in integrated clusters. f, Percentage of multi-probe-reactive B cells binding PE-SA-oligo by ELISA. g, Rate of multi-probe-reactive B cells demonstrating polyreactivity as determined by ELISA. The number in the center of each pie chart indicates the number of B cells / mAb analyzed. [Figure 10] Figure 10a-e. SARS-CoV-2-specific B cells constitute multiple distinct clusters. (a) Model showing antigen probe preparation and representative gating strategy for sorting antigen-positive B cells. (b) Integrated transcriptional UMAP analysis of distinct B cell clusters (n=42 samples from severe acute [n=10], convalescent visit 1 [n=28], and convalescent visit 2 [n=4] cohorts; 55,656 cells). (c) Cluster quality scores determined by ROGUE analysis. (d) UMAP projection showing antigen-specific cells used for all downstream analyses and the clusters from which they originated. (e) Quantitative depiction of antigen-specific cells and their distribution across distinct clusters. [Figure 11A]Figure 11a-c. B cell receptor and transcriptional analysis reveals cluster identity. (a) B cell receptor isotype usage, somatic hypermutation (SHM), and antigen reactivity by cluster for all combined samples. SHM data are plotted with an overlay showing median values with interquartile ranges. (b) Heatmap showing differentially expressed genes across clusters. A summary of cluster identity is provided below. (c) UMAP projection, where cell colors indicate gene module scoring for the indicated B cell subsets. See also Tables S5 and S6. [Figure 11B] See the legend to Figure 11A. [Figure 11C] See the legend to Figure 11A. [Figure 12-1] Figure 12a-j. B cell immunodominance and adaptive landscapes differ between acute and convalescent infections. (a) UMAP projections showing cells colored by blood draw time point. Sev acute, severe acute; Conv v1, convalescent visit 1; Conv v2, convalescent visit 2. (b) UMAP projections showing cells binding to specific antigens colored by blood draw time point. (c) Percentage of B cells targeting distinct antigens by cohort. Four Conv v1 and Conv v2 subjects presented at matched visits. (d-f) Quantification of B cell subsets targeting distinct antigens across cohorts. See also Figure 11B bottom for the clusters used to define B cell subsets. Numbers above the bars indicate the number of specific cells isolated. (g) Percentage of total antigen-specific memory B cells approximately 1.5 to 4.5 months (mo) after onset of illness in four matched convalescent subjects. Statistics are chi-squared, ****p<0.0001. (h) Variable heavy chain (VH) somatic hypermutation (SHM) of antigen-specific B cells across both recovery time points for four matched subjects. Statistics are unpaired nonparametric Mann-Whitney test, **p=0.0021 and ****p<0.0001. (i and j) Antigen-specific memory B cells at Conv v1 (I) and Conv v2 time points (J) for four matched subjects, separated by tertiles of SHM. [Figure 12-2]See the description of Figure 12-1. [Figure 13] Figure 13a-f. B cells targeting distinct antigens show unique variable gene usage. (a-e) Heatmap showing the frequency of heavy and light chain gene pairings for B cells binding the indicated antigens using combined data from all cohorts (left; legend indicates cell count / pairing), and dendrogram showing the top 10 variable heavy chain (VH) gene usage for Conv v1 (n=28) and Conv v2 (n=4) cohorts (right). The cell count / antigen encompassing the top 10 indicated VH genes is shown below each dendrogram. (f) Circos plot showing the top 10 shared heavy and light chain gene pairings across four matched Conv v1 (left; n=1,293 cells) and Conv v2 (right; n=1,438 cells) subjects. Total antigen-specific cells for SARS2 spike and RBD, HCoV spike, ORF8, and NP are shown. [Figure 14]Figure 14a-h. Neutralizing and in vivo protective potency of mAbs against SARS-CoV-2 spike and intracellular proteins. (a) Antigen binding curves for antigen-specific mAbs by ELISA. The dashed line at y=0.5 on the ELISA curves represents an OD405 cutoff of 0.5 for positivity (Spike, n=43; NP, n=19; ORF8, n=24). Data are representative of two or three independent experiments. See also Table S7. (b) Neutralizing potency (log10 PFU / ml) of mAbs tested by SARS-CoV-2 virus plaque assay. RBD, n=33; spike non-RBD, n=13; NP, n=18; ORF8, n=24. The dashed line at x=6.5 indicates the cutoff for neutralization. Statistics are nonparametric Kruskal-Wallis with Dunn's post-hoc test for multiple comparisons, ****p<0.0001. Data are representative of one independent experiment. (c) Body weight change in hamsters challenged intranasally with SARS-CoV-2 followed by therapeutic intraperitoneal (ip) administration of anti-RBD antibodies (mean ± SD, n = 4 biological replicates for each mAb). Control conditions were PBS injection or injection of an unrelated Ebola virus anti-GP133 mAb. (d) SARS-CoV-2 viral titers in lungs recovered from hamsters after challenge in (c). Bars indicate mean ± SD. Statistics are unpaired, nonparametric Kruskal-Wallis with Dunn's post-hoc test for multiple comparisons; *p = 0.0135, ***p = 0.0011, and **p = 0.0075. (e) Body weight change in mice challenged intranasally with SARS-CoV-2 followed by therapeutic ip administration of an anti-ORF8 antibody cocktail (mean ± SD, n = 3 biological replicates for each mAb). (f) SARS-CoV-2 viral titers in lungs recovered from mice after challenge in (e). Titers are expressed as N gene copies compared to a standard curve, and bars indicate the mean ± SD. Statistics performed were nonparametric Kruskal-Wallis with Dunn's post-hoc test for multiple comparisons, and no significant differences were found.(g) Body weight change in hamsters challenged intranasally with SARS-CoV-2 followed by therapeutic intraperitoneal (ip) administration of anti-NP antibody (mean ± SD, n = 4 biological replicates for each mAb). (h) SARS-CoV-2 viral titers in lungs recovered from hamsters after challenge shown in (g). Bars indicate mean ± SD. Statistics performed were nonparametric Mann-Whitney tests; no significant differences were found. [Figure 15-1]Figure 15a-n. Antigen specificity and B cell subset distribution are linked to clinical characteristics. (a) Distribution of total antigen-specific B cell reactivity per subject for the Convalescent Visit 1 cohort (n=28). (b-d) Distribution of total antigen-specific B cell reactivity by age (b), disease severity (c), and gender (d). Statistics are chi-square post-hoc tests with Holm-Bonferroni adjustment, **p=0.0012 and ****p<0.0001; ns, not significant. For age groups: 19-35 years, n=1,382 cells, 8 subjects; 36-49 years, n=5,319 cells, 13 subjects; 50-70 years, n=1,813 cells, 7 subjects. For severity groups, mild, n=990 cells, 4 subjects; moderate, n=4,462 cells, 13 subjects; severe, n=3,062 cells, 11 subjects. For gender, female, n=5,005 cells, 14 subjects; male, n=3,509 cells, 14 subjects. (e) Antigen-specific memory B cell (MBC; top) or naive B cell (bottom) reactivity by age group. Statistics are chi-squared post-hoc tests with Holm-Bonferroni adjustments, *p=0.0145 and ****p<0.0001; ns, not significant. (f) Antigen-specific MBC (top) or naive B cell (bottom) reactivity by disease severity. Statistics are chi-squared post-hoc tests with Holm-Bonferroni adjustments, *p=0.0143 and ****p<0.0001; ns, not significant. (g) Variable heavy chain (VH) somatic hypermutation (SHM) for MBC by age group (overlay shows median with interquartile range). Statistics are unpaired nonparametric ANOVA with Tukey's test for multiple comparisons; **p=0.002, ***p=0.0008, and ****p<0.0001. (h-j) Antigen-specific MBC by age divided by SHM tertiles. (k) Distribution of B-cell subsets by subject. (l-n) B-cell subset distribution by age (l), disease severity (m), and sex (n). Statistics are chi-square post-hoc tests with Holm-Bonferroni adjustment; ***p=0.0007 and ****p<0.0001; ns, not significant. For each group, n is the same as in (b)-(d). [Figure 15-2]See the description of Figure 15-1. [Figure 16-1] Figure 16a-d. B cell cluster distribution and antigen specificity by subject, related to Figure 10. (a-b) Overall cluster distribution (top) and antigen specificity distribution (bottom) for subjects screened using SARS2 spike (S), SARS2 RBD, NP, and ORF8 antigens with (a) or without (b) an endemic HCoV cocktail composed of S proteins from the 229E, NL63, OC43, and HKU1 strains. (c) Integrated UMAP analysis showing cluster distribution for two severe acute subjects (R3 and R6) at early (days 0, 1, and 3) and late (days 7 and 14) pooled sample collection timepoints after convalescent plasma therapy (left) and summary of cluster distribution by timepoint (right). (d) Distribution of antigen reactivity for severe acute subjects R3 and R6 at early and late pooled timepoints after convalescent plasma therapy. Statistics are chi-squared, ns = not significant. [Figure 16-2] See the description of Figure 16-1. [Figure 17-1] Figure 17a-d. Expression maps of selected genes related to Figure 11. (a-d) UMAP projections in which cells are colored by the expression levels of indicated genes associated with naive B cells (a), memory B cells (b), antibody-secreting cells (c), and mucosal homing (d). See also Table S6. [Figure 17-2] See the description of Figure 17-1. [Figure 18-1]Figure 18a-j. Related to Figure 12, further analysis of antigen-specific B cell signatures across separate cohorts and time points. (a-c) Variable heavy chain (VH) somatic hypermutation (SHM) by antigen-specific B cells shown for severe acute (a; n=10), Conv v1 (b, n=28), or Conv v2 subjects (c; n=4). Overlay shows median with interquartile range. (d) Distribution of memory B cell specificities across visit time points for four matched Conv v1 and Conv v2 subjects sampled approximately 1.5 and 4.5 months after disease onset. See also Table S1 for sampling times. (e-g) B cell receptor isotype utilization by antigen-specific B cells shown for severe acute (e; n=10), Conv v1 (f; n=28), or Conv v2 subjects (g; n=4). (h-j) Total anti-immunoglobulin (Ig) serum titers across time points for 16 matched convalescent subjects shown for SARS2 spike (h), NP (i), and ORF8 antigens (j). The dashed line at y=45 indicates the cutoff for positivity; values are shifted in (j) to avoid overlap. Statistics are paired nonparametric Wilcoxon tests, *p=0.0386. Data are representative of two independent experiments. [Figure 18-2] See the description of Figure 18-1. [Figure 19]Figure 19a-f. Correlation between antigen-probe positive B cells and serum titers, related to Figure 12. (a) Matched total anti-immunoglobulin (Ig) serum titers against spike, NP, and ORF8 antigens for Conv v1 subjects (n=28). Statistics are paired nonparametric Friedman test with Dunn's post-hoc test for multiple comparisons, ****p<0.0001; ***p=0.0002; ns=not significant. Data are representative of two independent experiments. (b) Matched antigen-specific probe hits by Conv v1 subject (n=28). Statistics are paired nonparametric Friedman test with Dunn's post-hoc test for multiple comparisons, ns=not significant. (c-e) Percentage of spike (d), NP (e), or ORF8 (f)-specific B cells in Conv v1 subjects (n=28) compared with serum titer levels against the same antigens. Statistics are nonparametric Spearman correlations, two-tailed, CI = 95%, ns = not significant. Data are representative of two independent experiments. (f) MAbs cloned from nonspecific polyreactive B cells tested for polyreactivity (left) and PE-SA binding (right) by ELISA (n = 10). Data are representative of one independent experiment. [Figure 20] Figures 20a-d. Related to Figure 15, additional analysis of antigen reactivity by clinical parameters. (a) Percentage of antigen-specific memory B cells (MBC) shown by Conv v1 subjects by age. Age increases from left to right along the graph. (b) Percentage of ORF8-specific MBC versus age for female (F) Conv V1 subjects (n=14). Statistics are non-parametric Spearman correlation, two-tailed, CI=95%. P values are shown. (c) Percentage of ORF8-specific MBC versus age for male (M) Conv V1 subjects (n=14). Statistics are non-parametric Spearman correlation, two-tailed, CI=95%. P values are shown, ns=not significant. (d) Percentage of antigen-specific naive-like B cells shown for each Conv v1 subject by severity. Severity score increases from left to right along the graph. See also Table S1 for severity scores by subject. DETAILED DESCRIPTION OF THE INVENTION
[0177] Detailed Description of the Invention The discovery of durable memory B cell (MBC) subsets specific to neutralizing viral epitopes is crucial for determining immune correlates of protection against SARS-CoV-2 infection. Here, we identified functionally distinct SARS-CoV-2-reactive B cell subsets by profiling the repertoire of convalescent COVID-19 patients using a high-throughput B cell sorting and sequencing platform. Utilizing barcoded SARS-CoV-2 antigen baits, we isolated thousands of B cells that segregated into distinct functional subsets specific for spike, nucleocapsid protein (NP), and open reading frame (ORF) proteins 7a and 8. Spike-specific B cells were enriched in classical MBC clusters, and monoclonal antibodies (mAbs) derived from these cells were potently neutralizing. In contrast, ORF8- and NP-specific B cells were enriched in naive and innate-like clusters, and mAbs against these targets were exclusively non-neutralizing. Finally, we demonstrated that B cell specificity, subset distribution, and affinity maturation are influenced by clinical characteristics such as age, sex, and symptom duration. Collectively, our data provide a comprehensive tool for assessing B cell immunity to SARS-CoV-2 infection or vaccination and highlight the complexity of human B cell responses to SARS-CoV-2.
[0178] I. Antibodies Aspects of the present disclosure relate to antibodies, antigen-binding fragments thereof, or polypeptides capable of specifically binding to the SARS-CoV-2 spike (S) protein, NP protein, or ORF8. A particular aspect relates to antibodies, or fragments thereof, that specifically bind to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein.
[0179] The term "antibody" refers to an intact immunoglobulin of any isotype or fragment thereof that can compete with the intact antibody for specific binding to a target antigen, including chimeric, humanized, fully human, and bispecific antibodies. As used herein, the terms "antibody" or "immunoglobulin" are used interchangeably and refer to any of several classes of structurally related proteins that function as part of an animal's immune response, including IgG, IgD, IgE, IgA, IgM, and related proteins, as well as polypeptides containing antibody CDR domains that retain antigen-binding activity.
[0180] The term "antigen" refers to a molecule or portion of a molecule capable of being bound by a selective binding agent, such as an antibody. An antigen can possess one or more epitopes capable of interacting with different antibodies.
[0181] The term "epitope" includes any region or portion of a molecule capable of eliciting an immune response by binding to an immunoglobulin or T-cell receptor. Epitopic determinants may include chemically active surface groups such as amino acids, sugar side chains, phosphoryl or sulfonyl groups, and may have specific three-dimensional structural characteristics and / or specific charge characteristics. Generally, antibodies specific for a particular target antigen will preferentially recognize epitopes on that target antigen within a complex mixture.
[0182] The epitope region of a given polypeptide can be identified using many different epitope mapping techniques known in the art, including X-ray crystallography, nuclear magnetic resonance spectroscopy, site-directed mutagenesis mapping, and protein display arrays, see, for example, Epitope Mapping Protocols, (Johan Rockberg and Johan Nilvebrant, Ed., 2018) Humana Press, New York, NY. Such techniques are known in the art and are described, for example, in U.S. Patent No. 4,708,871; Geysen et al. Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984); Geysen et al. Proc. Natl. Acad. Sci. USA 82:178-182 (1985); Geysen et al. Molec. Immunol. 23:709-715 (1986). Additionally, antigenic regions of proteins can be predicted and identified using standard antigenicity and hydropathy plots.
[0183] The term "immunogenic sequence" refers to a molecule containing the amino acid sequence of at least one epitope capable of stimulating the production of antibodies in an appropriate host. The term "immunogenic composition" refers to a composition containing at least one immunogenic molecule (e.g., an antigen or carbohydrate).
[0184] Intact antibodies generally consist of two full-length heavy chains and two full-length light chains, although in some cases they may contain fewer chains, such as antibodies naturally occurring in camelids, which may contain only heavy chains. Antibodies as disclosed herein may be derived from only one source or may be "chimeric," i.e., different portions of the antibody may be derived from two different antibodies. For example, the variable or CDR regions may be derived from a rat or mouse source, while the constant region is derived from a different animal source, such as a human. Antibodies or binding fragments may be produced in hybridomas, by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact antibodies. Unless otherwise indicated, the term "antibody" includes derivatives, variants, fragments, and muteins thereof, examples of which are described below (Sela-Culang et al., Front Immunol. 2013;4:302;2013).
[0185] The term "light chain" includes full-length light chains and fragments thereof having sufficient variable region sequence to confer binding specificity. Full-length light chains have a molecular weight of approximately 25,000 daltons and contain a variable region domain (abbreviated herein as VL) and a constant region domain (abbreviated herein as CL). There are two distinct classifications of light chains: kappa (κ) and lambda (λ). The term "VL fragment" refers to a fragment of the light chain of a monoclonal antibody containing all or a portion of the light chain variable region, including the CDRs. A VL fragment may further contain a light chain constant region sequence. The light chain variable region domain is located at the amino terminus of the polypeptide.
[0186] The term "heavy chain" includes full-length heavy chains and fragments thereof having sufficient variable region sequence to confer binding specificity. A full-length heavy chain has a molecular weight of approximately 50,000 daltons and contains a variable region domain (abbreviated herein as VH) and three constant region domains (abbreviated herein as CH1, CH2, and CH3). The term "VH fragment" refers to a fragment of the heavy chain of a monoclonal antibody containing all or part of the heavy chain variable region, including the CDRs. A VH fragment can further contain a heavy chain constant region sequence. The number of heavy chain constant region domains depends on the isotype. The VH domain is at the amino terminus of the polypeptide, and the CH domain is at the carboxy terminus, with CH3 being closest to the -COOH end. Antibody isotypes can be IgM, IgD, IgG, IgA, or IgE and are defined by the heavy chain present, of which there are five categories: mu (μ), delta (δ), gamma (γ), alpha (α), or epsilon (ε). IgG has several subtypes, including, but not limited to, IgG1, IgG2, IgG3, and IgG4. IgM subtypes include IgM1 and IgM2. IgA subtypes include IgA1 and IgA2.
[0187] A. Types of Antibodies Antibodies can be whole immunoglobulins of any isotype or classification, chimeric antibodies, or hybrid antibodies having specificity for more than one antigen. They can also be fragments (e.g., F(ab')2, Fab', Fab, Fv, etc.), including hybrid fragments. Immunoglobulins also include natural, synthetic, or genetically engineered proteins that act like antibodies by binding to specific antigens to form complexes. The term antibody includes genetically engineered or otherwise modified forms of immunoglobulins.
[0188] The term "monomer" refers to an antibody containing only one Ig unit. A monomer is the basic functional unit of an antibody. The term "dimer" refers to an antibody containing two Ig units attached to each other via the constant domains (Fc regions, or fragment crystallizable regions) of the antibody heavy chains. The complex may be stabilized by a joining (J) chain protein. The term "multimer" refers to an antibody containing more than two Ig units attached to each other via the constant domains (Fc regions) of the antibody heavy chains. The complex may be stabilized by a joining (J) chain protein.
[0189] The term "bivalent antibody" refers to an antibody that comprises two antigen-binding sites. The two binding sites may have the same antigen specificity or they may be bispecific, meaning that the two antigen-binding sites have different antigen specificities.
[0190] Bispecific antibodies are a class of antibodies with two paratopes that have different binding sites for two or more distinct epitopes. In some embodiments, bispecific antibodies can be biparatopic, meaning that they can specifically recognize different epitopes from the same antigen. In some embodiments, bispecific antibodies can be constructed from a pair of different single-domain antibodies called "nanobodies." Single-domain antibodies are sourced and engineered from cartilaginous fish and camelids. Nanobodies can be linked together by linkers using techniques common to those skilled in the art; such methods for selecting and linking nanobodies are described in PCT Publication Nos. WO2015044386A1, WO2010037838A2, and Bever et al., Anal Chem. 86:7875-7882 (2014), each of which is specifically incorporated herein by reference in its entirety.
[0191] Bispecific antibodies can be constructed as whole IgG, Fab'2, Fab'PEG, diabodies, or alternatively as scFvs. Diabodies and scFvs can be constructed without an Fc region, using only variable domains, potentially reducing the effects of anti-idiotypic reaction. Bispecific antibodies can be produced by a variety of methods, including, but not limited to, fusion of hybridomas or linking of Fab' fragments. See, for example, Songsivilai and Lachmann, Clin. Exp. Immunol. 79:315-321 (1990); Kostelny et al., J. Immunol. 148:1547-1553 (1992), each of which is specifically incorporated by reference in its entirety.
[0192] In certain aspects, the antigen-binding domain can be multispecific or heterospecific by multimerizing pairs of VH and VL domains that bind to different antigens. For example, the antibody can bind to or interact with (a) a cell surface antigen, (b) an Fc receptor on the surface of an effector cell, or (c) at least one other component. Thus, aspects can include, but are not limited to, bispecific, trispecific, tetraspecific, and other multispecific antibodies or antigen-binding fragments thereof directed to epitopes and other targets, such as Fc receptors on effector cells.
[0193] In some embodiments, multispecific antibodies can be used and directly linked via short flexible polypeptide chains using routine methods known in the art. One such example is a diabody, a bivalent, bispecific antibody, in which the VH and VL domains are expressed on a single polypeptide chain but are paired with complementary domains on another chain to create two antigen-binding sites using a linker that is too short to allow pairing between the domains on the same chain. This linker functionality is applicable to triabodies, tetrabodies, and even higher antibody multimeric embodiments (see, e.g., Hollinger et al., Proc Natl. Acad. Sci. USA 90:6444-6448 (1993); Polijak et al., Structure 2:1121-1123 (1994); Todorovska et al., J. Immunol. Methods 248:47-66 (2001)).
[0194] In contrast to bispecific whole antibodies, bispecific diabodies can also be advantageous because they can be easily constructed and expressed in Escherichia coli (E. coli). Diabodies (and other polypeptides, such as antibody fragments) with appropriate binding specificities can be easily selected from libraries using phage display (WO94 / 13804). If one arm of the diabody is kept constant, e.g., the specificity directed against a protein is maintained, a library can be produced in which the other arm is varied, and antibodies with the appropriate specificity can be selected. Bispecific whole antibodies can be produced by alternative engineering methods, such as those described in Ridgeway et al. (Protein Eng., 9:616-621, 1996) and Krah et al. (N Biotechnol. 39:167-173, 2017), each of which is incorporated herein by reference in its entirety.
[0195] Heteroconjugate antibodies are composed of two covalently linked monoclonal antibodies with different specificities. See, e.g., U.S. Patent No. 6,010,902, incorporated herein by reference in its entirety.
[0196] The portion of an Fv fragment of an antibody molecule that binds to an antigen epitope with high specificity is referred to herein as the "paratope." The paratope consists of amino acid residues that contact the antigen epitope and promote antigen recognition. Each of the two Fv fragments of an antibody is composed of two variable domains, VH and VL, in a dimerized configuration. The primary structure of each variable domain contains three hypervariable loops separated by and adjacent to framework regions (FR). Hypervariable loops are the regions of greatest primary sequence variability among antibody molecules from any mammal. The term hypervariable loop is sometimes used interchangeably with the term "complementarity-determining region (CDR)." The length of the hypervariable loops (or CDRs) varies among antibody molecules. The framework regions of all antibody molecules from a given mammal share a high degree of primary sequence similarity / consensus. The consensus of the framework regions can be used by those skilled in the art to identify both the framework regions and the hypervariable loops (or CDRs) interspersed between the framework regions. Hypervariable loops are given names that distinguish their location within the polypeptide and the domain in which they occur. The CDRs in the VL domain are identified as L1, L2, and L3, with L1 being the most distal and L3 being closest to the CL domain. CDRs can also be named CDR-L1, CDR-L2, and CDR-L3. L3 (CDR-L3) is generally the most variable region among all antibody molecules produced by a given organism. CDRs are regions of the polypeptide chain that are linearly arranged in the primary structure and separated from each other by framework regions. The amino-terminal (N-terminal) end of the VL chain is designated FR1. The region designated FR2 is located between the L1 hypervariable loop and the L2 hypervariable loop. FR3 is located between the L2 hypervariable loop and the L3 hypervariable loop, and the FR4 region is closest to the CL domain. This structure and nomenclature is repeated for the VH chain, which contains three CDRs identified as CDR-H1, CDR-H2 and CDR-H3. The majority of amino acid residues in the variable domains or Fv fragments (VH and VL) are part of the framework regions (approximately 85%).The three-dimensional or tertiary structure of an antibody molecule is such that the framework regions are more interior to the molecule and provide the majority of its structure, while the CDRs are on the exterior of the molecule.
[0197] Several methods have been developed and can be used by those skilled in the art to identify the exact amino acids that make up each of these regions. This can be done using any of several sequence alignment methods and algorithms that identify the conserved amino acid residues that make up the framework regions, and therefore identify the CDRs that are located between the framework regions, which may vary in length. Three commonly used methods have been developed for identifying antibody CDRs: Kabat (as described in T.T. Wu and E.A. Kabat, "AN ANALYSIS OF THE SEQENCES OF THE VARIABLE REGIONS OF BENCE JONES PROTEINS AND MYELOMA LIGHT CHAINS AND THEIR IMPLICATIONS FOR ANTIBODY COMPLEMENTARITY," J. Exp. Med., vol. 132, no. 2, pp. 211-250, August 1970); Chothia (as described in C. Chothia et al., "Conformations of immunoglobulin hypervariable regions," Nature, vol. 342, no. 6252, pp. 877-883, December 1989); and IMGT (M.-P. Lefranc et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains"). (As described in "Variable Domains," Developmental & Comparative Immunology, vol. 27, no. 1, pp. 55-77, Jan. 2003). Each of these methods involves a unique numbering system for identifying the amino acid residues that make up the variable regions. In most antibody molecules, the amino acid residues that actually contact the epitope of the antigen are located in the CDRs, but in some cases, residues in the framework regions contribute to antigen binding.
[0198] Those skilled in the art can use any of several methods to determine the paratope of an antibody. These methods include: 1) Computer prediction of the tertiary structure of antibody / epitope binding interactions based on the chemical nature of the amino acid sequence of the antibody variable region and the composition of the epitope. 2) Hydrogen-deuterium exchange and mass spectrometry. 3) A polypeptide fragmentation and peptide mapping approach in which multiple overlapping peptide fragments are generated from the full length of a polypeptide and the binding affinity of these peptides to the epitope is assessed. 4) Antibody phage display library analysis, in which mammalian antibody Fab fragment-encoding genes are expressed by bacteriophage so that they are incorporated into the phage coat. This population of Fab-expressing phage is then allowed to interact with antigen, which can be immobilized or expressed by a different exogenous expression system. Unbound Fab fragments are washed away, leaving only specifically bound Fab fragments attached to the antigen. The bound Fab fragments can be easily isolated, and the genes encoding them can be determined. This approach can also be used for Fv fragments or smaller regions of Fab fragments containing specific VH and VL domains, if desired.
[0199] In certain aspects, affinity matured antibodies are enhanced by one or more modifications in one or more of their CDRs, improving the affinity of the antibody to the target antigen compared to the parent antibody that does not have these modifications.Some affinity matured antibodies have nanomolar or picomolar affinity to the target antigen.Affinity matured antibodies are produced by methods known in the art, for example, Marks et al., Bio / Technology 10:779 (1992) describes affinity maturation by VH and VL domain shuffling, and random mutagenesis of CDR and / or framework residues used in phage display is described by Rajpal et al., PNAS.24:8466-8471 (2005) and Thie et al., Methods Mol Biol.525:309-22 (2009), and is combined with computational methods such as those demonstrated in Tiller et al., Front. Immunol.8:986 (2017).
[0200] Chimeric immunoglobulins are the product of fusion genes derived from different species; "humanized" chimeras generally have framework regions (FR) derived from a human immunoglobulin and one or more CDRs derived from a non-human source.
[0201] In certain aspects, a portion of the heavy and / or light chain is identical to or homologous to a corresponding sequence from another specific species or belonging to a specific antibody class or subclass, while the remainder of the chain is identical to or homologous to a corresponding sequence in an antibody from another species or belonging to another antibody class or subclass, and to a fragment of such an antibody, so long as it exhibits the desired biological activity. U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851 (1984). For methods relating to chimeric antibodies, see, e.g., U.S. Patent No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1985), each of which is specifically incorporated herein by reference in its entirety. CDR grafting is described, for example, in U.S. Patent Nos. 6,180,370, 5,693,762, 5,693,761, 5,585,089, and 5,530,101, all of which are incorporated herein by reference for all purposes.
[0202] In some embodiments, minimizing antibody polypeptide sequences derived from non-human species optimizes the function and reduces immunogenicity of chimeric antibodies. Certain amino acid residues from non-antigen-recognition regions of non-human antibodies are modified to be homologous to corresponding residues in human antibodies or isotypes. One example is a "CDR-grafted" antibody, in which an antibody contains one or more CDRs derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the antibody chain is identical or homologous to corresponding sequences in an antibody derived from another species or belonging to another antibody class or subclass. For use in humans, human antibody framework regions are grafted onto the V regions, consisting of CDR1, CDR2, and partial CDR3 of both the light and heavy chain variable regions from a non-human immunoglobulin, replacing the naturally occurring antigen receptor of the human antibody with the non-human CDR. In some cases, corresponding non-human residues are replaced with framework region residues from a human immunoglobulin. Furthermore, humanized antibodies can contain residues not found in the recipient or donor antibody to further refine performance. The humanized antibody can also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. See, e.g., Jones et al., Nature 321:522 (1986); Riechmann et al., Nature 332:323 (1988); Presta, Curr. Op. Struct. Biol. 2:593 (1992); Vaswani and Hamilton, Ann. Allergy, Asthma and Immunol. 1:105 (1998); Harris, Biochem. Soc. Transactions 23:1035 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428 (1994); Verhoeyen et al., Science 239:1534-36 (1988).
[0203] Intrabodies are intracellularly located immunoglobulins that bind to intracellular antigens, as opposed to secreted antibodies that bind to antigens in the extracellular space.
[0204] Polyclonal antibody preparations typically contain different antibodies directed against different determinants (epitopes). To produce polyclonal antibodies, a host, such as a rabbit or goat, is immunized with an antigen or antigen fragment, typically with an adjuvant and, if necessary, coupled to a carrier. Antibodies directed against the antigen are then recovered from the host's serum. Polyclonal antibodies can be affinity purified against the antigen to render them monospecific.
[0205] A monoclonal antibody or "mAb" refers to an antibody obtained from a homogeneous population of antibodies from a single parent cell, e.g., the population is identical except for naturally occurring mutations that may be present in minor amounts. Each monoclonal antibody is directed against a single antigenic determinant.
[0206] B. Functional Antibody Fragments and Antigen-Binding Fragments 1. Antigen-binding fragments Certain aspects relate to antibody fragments, such as antibody fragments that bind to the SARS-CoV-2 spike protein. The term functional antibody fragment includes antigen-binding fragments of antibodies that retain the ability to specifically bind to an antigen. These fragments are composed of variable regions, heavy chain (VH) and / or light chain (VL), in various configurations; in some embodiments, they contain constant regions, heavy chain 1 (CH1) and light chain (CL). In some embodiments, they lack the Fc region, which is composed of heavy chain 2 (CH2) and heavy chain 3 (CH3) domains. Embodiments of antigen-binding fragments and modifications thereof may include: (i) Fab fragment type, consisting of VL, VH, CL and CH1 domains; (ii) Fd fragment type, consisting of VH and CH1 domains; (iii) Fv fragment type, consisting of VH and VL domains; (iv) single domain fragment type dAb, consisting of a single VH or VL domain (Ward, 1989; McCafferty et al., 1990; Holt et al., 2003); and (v) isolated complementarity-determining region (CDR) regions. Such terms are described, for example, in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1989); Molec. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, RA (ed.), New York: VCH Publisher, Inc.); Huston et al., Cell Biophysics, 22:189-224 (1993); Pluckthun and Skerra, Meth. Enzymol., 178:497-515 (1989) and Day, ED, Advanced Immunochemistry, 2d ed., Wiley-Liss, Inc. New York, NY (1990); Antibodies, 4:259-277 (2015), each of which is incorporated by reference.
[0207] Antigen-binding fragments also include fragments of antibodies that retain exactly one, two, or three, at least one, two, or three, or at most one, two, or three complementarity-determining regions (CDRs) from the light chain variable region. Fusions of CDR-containing sequences to an Fc region (or CH2 or CH3 regions thereof) are included within this definition, including, for example, scFvs fused directly or indirectly to an Fc region as encompassed herein.
[0208] The term Fab fragment (also "Fab") refers to a monovalent antigen-binding fragment of an antibody containing the VL, VH, CL, and CH1 domains. The term Fab' fragment refers to a monovalent antigen-binding fragment of a monoclonal antibody that is larger than the Fab fragment. For example, a Fab' fragment contains the VL, VH, CL, and CH1 domains and all or part of the hinge region. The term F(ab')2 fragment refers to a bivalent antigen-binding fragment of a monoclonal antibody that contains two Fab' fragments linked by a disulfide bridge at the hinge region. An F(ab')2 fragment contains, for example, all or part of two VH and VL domains, and may further contain all or part of two CL and CH1 domains.
[0209] The term Fd fragment refers to a fragment of a monoclonal antibody heavy chain containing all or part of the VH, including the CDRs. The Fd fragment may further contain a CH1 region sequence.
[0210] The term Fv fragment refers to a monovalent antigen-binding fragment of a monoclonal antibody that contains all or part of the VL and VH domains, but lacks the CL and CH1 domains. The VL and VH contain, for example, the CDRs. A single-chain antibody (sFv or scFv) is an Fv molecule in which the VL and VH domains are connected by a flexible linker to form a single polypeptide chain that forms the antigen-binding fragment. Single-chain antibodies are discussed in detail in International Patent Application Publication No. WO 88 / 01649 and U.S. Pat. Nos. 4,946,778 and 5,260,203, the disclosures of which are incorporated herein by reference. The term (scFv)2 refers to a bivalent or bispecific sFv polypeptide chain that contains an oligomerization domain at the C-terminus separated from the sFv by a hinge region (Pack et al. 1992). The oligomerization domain contains self-associating a-helices, e.g., leucine zippers, which may be further stabilized by additional disulfide bonds. (scFv)2 fragments are also known as "miniantibodies" or "minibodies."
[0211] Single-domain antibodies are antigen-binding fragments that contain only a VH or VL domain. In some cases, two or more VH regions are covalently linked with a peptide linker to create a bivalent domain antibody. The two VH regions of a bivalent domain antibody can target the same or different antigens.
[0212] 2. Fragment antigen-binding region Fab The Fab polypeptides of the present disclosure include Fab antigen-binding fragments of antibodies. Unless otherwise specified, the term "Fab" refers to a polypeptide excluding the Fc portion of an antibody. Fab can be conjugated to polypeptides containing other components, such as additional antigen-binding domains, costimulatory domains, linkers, peptide spacers, transmembrane domains, endodomains, and accessory proteins. Fab polypeptides can be produced using conventional techniques known in the art and are well described in the literature.
[0213] 3. Fragment crystallizable region Fc The Fc region contains two heavy chain fragments comprising the CH2 and CH3 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by the hydrophobic interaction of the CH3 domain. The term "Fc polypeptide" as used herein includes native and mutein forms of polypeptides derived from the Fc region of an antibody. It also includes truncated forms of such polypeptides that contain the hinge region that promotes dimerization.
[0214] C. Antibody CDRs & Polypeptides with Scaffold Domains Presenting the CDRs According to various embodiments, antigen-binding peptide scaffolds such as complementarity-determining regions (CDRs) are used to create protein-binding molecules.Generally, those skilled in the art can determine the type of protein scaffold to which at least one CDR is grafted.It is known that optimally, scaffolds must meet several criteria, such as good phylogenetic conservation; known three-dimensional structure; small size; little or no post-transcriptional modification; and / or easy production, expression and purification.Skerra, J Mol Recognit, 13:167-87 (2000).
[0215] Protein scaffolds can be provided by, but are not limited to, fibronectin type III FN3 domain (also known as "monobody"), fibronectin type III domain 10, lipocalin, anticalin, the Z-domain of Staphylococcus aureus protein A, thioredoxin A, or proteins with repeat motifs such as "ankyrin repeats," "armadillo repeats," "leucine-rich repeats," and "tetratricopeptide repeats." Such proteins are described in U.S. Patent Application Publication Nos. 2010 / 0285564, 2006 / 0058510, 2006 / 0088908, 2005 / 0106660, and PCT Publication No. WO2006 / 056464, each of which is specifically incorporated herein by reference in its entirety. Scaffolds derived from toxins of scorpions, insects, plants, mollusks, etc., and protein inhibitors of neuronal NO synthase (PIN) may also be used.
[0216] D. Antibody binding The term "selective binding agent" refers to a molecule that binds to an antigen. Non-limiting examples include antibodies, antigen-binding fragments, scFv, Fab, Fab', F(ab')2, single chain antibodies, peptides, peptide fragments, and proteins.
[0217] The term " binding " refers to the direct association between two molecules, for example, by covalent, electrostatic, hydrophobic and ionic and / or hydrogen bond interactions, including interactions such as salt bridges and water bridges. " Immunologically reactive " means that the target selective binding substance or antibody binds to the antigen present in biological sample. The term " immune complex " refers to the complex formed when antibody or selective binding substance binds to the epitope on antigen.
[0218] 1. Avidity The term "affinity" refers to the strength with which an antibody or selective binding agent binds to an epitope. In antibody binding reactions, this is expressed as an affinity constant (Ka or ka, sometimes referred to as the association constant) for a given antibody or selective binding agent. Affinity is measured as the binding strength of an antibody to its antigen compared to the binding strength of the antibody to an unrelated amino acid sequence. Affinity can be expressed, for example, as an antibody's ability to bind to its antigen being 20 times greater than to an unrelated amino acid sequence. As used herein, the term "avidity" refers to the resistance of a complex of two or more agents to dissociation after dilution. The terms "immunoreactive" and "preferentially bind" are used interchangeably herein with respect to antibodies and / or selective binding agents.
[0219] There are several experimental methods that can be used by those skilled in the art to evaluate the binding affinity of a given antibody or selective binding substance for its antigen. This is generally done by measuring the equilibrium dissociation constant (KD or Kd) using the equation KD = koff / kon = [A][B] / [AB]. The term koff is the dissociation rate of an antibody and an antigen per unit time and is related to the concentration of the antibody and antigen present in solution in unbound form at equilibrium. The term kon is the association rate of an antibody and an antigen per unit time and is related to the concentration of the bound antigen-antibody complex at equilibrium. The units used to measure KD are mol / L (molar concentration or M), or concentration. The Ka of an antibody is the inverse of KD and is determined by the equation Ka = 1 / KD. Examples of some experimental methods that can be used to determine KD values are enzyme-linked immunosorbent assay (ELISA), isothermal titration calorimetry (ITC), fluorescence polarization, surface plasmon resonance (SPR), and affinity capillary electrophoresis (ACE). The affinity constant (Ka) of an antibody is the inverse of KD and is determined by the equation Ka=1 / KD.
[0220] Antibodies that may be useful in certain embodiments include antibodies with a nucleotide sequence of approximately 10 6 , 10 7 , 108 , 10 9 Or 10 10 M, at least about 10 6 , 10 7 , 10 8 , 10 9 Or 10 10 M, or up to about 10 6 , 10 7 , 10 8 , 10 9 Or 10 10 M, or any range derivable therein. Similarly, in some embodiments, the antibody may have an affinity constant (Ka) of about 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 M, at least about 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 M, or up to about 10 -6 , 10 -7 , 10 -8 , 10 -9 , 10 -10 M, or any range derivable therein. These values are reported for the antibodies discussed herein, and the same assays may be used to assess the binding properties of such antibodies. Antibodies of the invention may have a dissociation constant (KD) of ≦10 -8 An antibody is said to "specifically bind" to its target antigen when it has a KD of ≤ 5 x 10 -9 High affinity when M and KD are ≤ 5 x 10 -10 When M, it specifically binds to the antigen with "very high affinity."
[0221] 2. Epitope specificity An epitope of an antigen is a specific region of the antigen to which an antibody has binding affinity. In the case of a protein or polypeptide antigen, an epitope is a specific residue (or particular amino acid or protein segment) to which an antibody binds with high affinity. An antibody does not necessarily contact every residue in a protein, nor does every amino acid substitution or deletion within a protein necessarily affect binding affinity. For purposes of this specification and the appended claims, the terms "epitope" and "antigenic determinant" are used interchangeably and refer to a site on an antigen to which B cells and / or T cells respond or recognize. Polypeptide epitopes can be formed from both contiguous amino acids and noncontiguous amino acids juxtaposed by tertiary folding of a polypeptide. Epitopes typically contain at least three, and typically 5-10, amino acids in a unique spatial arrangement.
[0222] The epitope specificity of an antibody can be determined in a variety of ways. One approach involves examining a collection of overlapping peptides of 15 amino acids that span the entire sequence of a protein and differ by a small number of amino acids (e.g., 3-30 amino acids). The peptides are immobilized in separate wells of a microtiter dish. Immobilization can be achieved, for example, by biotinylating one end of the peptide. Because this process can affect antibody affinity for the epitope, different samples of the same peptide can be biotinylated at the N- and C-termini and immobilized in separate wells for comparison. This is useful for identifying end-specific antibodies. Optionally, additional peptides can be included to terminate at specific amino acids of interest. This approach is useful for identifying end-specific antibodies against internal fragments. Antibodies or antigen-binding fragments are screened for binding to each of the various peptides. The epitope is defined as a segment of amino acids common to all peptides to which the antibody exhibits high affinity binding.
[0223] 3. Modification of antibody antigen-binding domain It is understood that antibodies of the present invention can be modified to be substantially identical to an antibody polypeptide sequence or fragment thereof while still binding to an epitope of the present invention. Polypeptide sequences are "substantially identical" if they share at least 80% sequence identity, at least 90% sequence identity, at least 95% sequence identity, at least 96% sequence identity, at least 97% sequence identity, at least 98% sequence identity, or at least 99% sequence identity, or any range therein, when optimally aligned using programs such as Clustal Omega, IGBLAST, GAP, or BESTFIT using default gap weights.
[0224] As discussed herein, minor variations in the amino acid sequence of an antibody or its antigen-binding region are contemplated as being encompassed by the present invention, provided that the variations in the amino acid sequence maintain at least 75%, more preferably at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, and most preferably at least 99% sequence identity. In particular, conservative amino acid substitutions are contemplated.
[0225] Conservative substitutions are substitutions that occur within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally classified into families based on the chemical properties of their side chains; for example, acidic (aspartic acid, glutamic acid), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). For example, it is reasonable to expect that a single substitution of a leucine moiety with an isoleucine or valine moiety, or a similar substitution with a structurally related amino acid from the same family of amino acids, especially if it does not involve an amino acid in a framework region, will not significantly affect the binding or properties of the resulting molecule. Whether an amino acid change results in a functional peptide can be easily determined by assaying the specific activity of the polypeptide derivative. One skilled in the art can perform standard ELISA, surface plasmon resonance (SPR) or other antibody binding assays to make a quantitative comparison of antigen binding affinity between an unmodified antibody and any polypeptide derivative with conservative substitutions made through any of several methods available to one skilled in the art.
[0226] Fragments or analogs of antibodies or immunoglobulin molecules can be readily prepared by those skilled in the art. Preferred amino and carboxy termini of fragments or analogs are located near the boundaries of functional domains. Structural and functional domains can be identified by comparing nucleotide and / or amino acid sequence data with public or private sequence databases. Preferably, computerized comparison methods are used to identify sequence motifs or predicted protein conformation domains present in other proteins of known structure and / or function. Standard methods for identifying protein sequences that fold into known three-dimensional structures are available to those skilled in the art; Dill and McCallum, Science 338:1042-1046 (2012). Several algorithms have been developed to predict protein structures and the gene sequences that encode them; many of these algorithms can be found at the National Center for Biotechnology Information (ncbi.nlm.nih.gov / guide / proteins / on the World Wide Web) and the Bioinformatics Resource Portal (expasy.org / proteomics on the World Wide Web). Thus, the foregoing examples demonstrate that one of skill in the art can recognize sequence motifs and structural conformations that can be used to define structural and functional domains in accordance with the present invention.
[0227] Framework modifications can be made to the antibody to reduce immunogenicity, e.g., by "backmutating" one or more framework residues to the corresponding germline sequence.
[0228] It is also envisioned that antigen-binding domains may be multispecific or multivalent by multimerizing the antigen-binding domain using pairs of VH and VL domains that bind either the same antigen (multivalent) or different antigens (multispecific).
[0229] E. Chemical Modification of Antibodies In some aspects, glycosylation variants of antibodies are also contemplated, in which the number and / or type of glycosylation sites are altered compared to the amino acid sequence of the parent polypeptide. Glycosylation of a polypeptide can be altered, for example, by modifying one or more glycosylation sites within the polypeptide sequence to increase the affinity of the polypeptide for an antigen (U.S. Patent Nos. 5,714,350 and 6,350,861). In certain embodiments, antibody protein variants contain more or fewer N-linked glycosylation sites than a native antibody. N-linked glycosylation sites are characterized by the sequence Asn-X-Ser or Asn-X-Thr, where the amino acid residue designated X can be any amino acid residue except proline. Substitution of amino acid residues to create this sequence provides a new potential site for the addition of an N-linked sugar chain. Alternatively, substitutions that eliminate or alter this sequence will prevent the addition of an N-linked sugar chain present in the native polypeptide. For example, glycosylation can be reduced by deleting Asn or substituting Asn with a different amino acid. In other embodiments, one or more new N-linked glycosylation sites are created. Antibodies typically have N-linked glycosylation sites in the Fc region.
[0230] Additional antibody variants include cysteine variants, in which one or more cysteine residues in the parent or native amino acid sequence are deleted or replaced with another amino acid (e.g., serine). Cysteine variants are particularly useful when the antibody must be refolded into a biologically active conformation. Cysteine variants may have fewer cysteine residues than native antibodies, typically an even number, to minimize interactions resulting from unpaired cysteines.
[0231] In some aspects, a polypeptide can be pegylated to increase biological half-life by reacting the polypeptide with polyethylene glycol (PEG) or a reactive ester or aldehyde derivative of PEG under conditions that result in one or more PEG groups being attached to the polypeptide. Polypeptide PEGylation can be carried out by an acylation reaction or an alkylation reaction using a reactive PEG molecule (or a similar reactive water-soluble polymer). Methods for pegylation of proteins are known in the art and can be applied to the polypeptides of the present invention to obtain PEGylated antibody derivatives. See, for example, EP 0 154 316 and EP 0 401 384. In some aspects, the antibody is conjugated or otherwise linked to transthyretin (TTR) or a TTR variant. TTR or a TTR variant can be chemically modified using, for example, a chemical selected from the group consisting of dextran, poly(n-vinylpyrrolidone), polyethylene glycol, propylene glycol homopolymer, polypropylene oxide / ethylene oxide copolymer, polyoxyethylated polyol, and polyvinyl alcohol. As used herein, the term "polyethylene glycol" is intended to encompass all forms of PEG that have been used to derivatize other proteins.
[0232] 1. Conjugation Derivatives of the antibodies and antigen-binding fragments described herein are also provided. Derivatized antibodies or fragments thereof can include any molecule or substance that confers desired properties to the antibody or fragment. Derivatized antibodies can include, for example, a detectable (or labeling) moiety (e.g., a radioactive, chromogenic, antigenic, or enzymatic molecule, or a detectable bead), a molecule that binds to another molecule (e.g., biotin or streptavidin), a therapeutic or diagnostic moiety (e.g., a radioactive, cytotoxic, or pharmaceutically active moiety), or a molecule that enhances the suitability of the antibody for a particular use (e.g., administration to a subject, e.g., a human subject, or other in vivo or in vitro use).
[0233] Optionally, antibodies or immunological portions of antibodies can be chemically conjugated to or expressed as fusion proteins with other proteins. In some aspects, polypeptides can be chemically modified by conjugating or fusing them to serum proteins such as human serum albumin to increase the half-life of the resulting molecule. See, for example, EP 0322094 and EP 0 486 525. In some aspects, polypeptides can be conjugated to diagnostic substances and used for diagnostic purposes, for example, to monitor the development or progression of disease and determine the effectiveness of a given treatment regimen. In some aspects, polypeptides can also be conjugated to therapeutic substances to provide treatments that combine the therapeutic effects of the polypeptide. Additional suitable conjugated molecules include ribonucleases (RNases), DNase I, antisense nucleic acids, inhibitory RNA molecules such as siRNA molecules, immunostimulatory nucleic acids, aptamers, ribozymes, triplex-forming molecules, and external guide sequences. These functional nucleic acid molecules can act as effectors, inhibitors, modulators, and stimulators of a specific activity possessed by a target molecule, or they can possess a de novo activity that is independent of any other molecule.
[0234] In some aspects, antibodies and antibody-like molecules are disclosed that are linked to at least one agent to form an antibody conjugate or payload. To enhance the effectiveness of antibody molecules as diagnostic or therapeutic agents, it is common to link, covalently bind, or complex at least one desired molecule or moiety to the antibody molecule. Such molecules or moieties can be, but are not limited to, at least one effector molecule or reporter molecule. Effector molecules include molecules with desired activity, such as cytotoxic activity. Non-limiting examples of effector molecules include toxins, therapeutic enzymes, antibiotics, radiolabeled nucleotides, etc. In contrast, reporter molecules are defined as any moiety that can be detected using an assay. Non-limiting examples of reporter molecules conjugated to antibodies include enzymes, radiolabels, haptens, fluorescent labels, phosphorescent molecules, chemiluminescent molecules, chromophores, luminescent molecules, photoaffinity molecules, colored particles, or ligands.
[0235] a. Types of conjugates A specific example of an antibody conjugate is a conjugate in which the antibody is linked to a detectable label. A "detectable label" is a compound and / or element that can be detected due to its specific functional and / or chemical properties, and can be used to detect and / or, if desired, further quantify the antibody. Examples of detectable labels include, but are not limited to, radioisotopes, fluorescers, semiconductor nanocrystals, chemiluminescent agents, chromophores, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, metal sols, ligands (e.g., biotin, streptavidin, or haptens), and the like. Specific examples of labels include, but are not limited to, horseradish peroxidase (HRP), fluorescein, FITC, rhodamine, dansyl, umbelliferone, dimethylacridinium ester (DMAE), Texas Red, luminol, NADPH, and α- or β-galactosidase. Antibody conjugates include those primarily intended for in vitro use, in which the antibody is linked to a secondary binding ligand and / or enzyme to produce a colored product upon contact with a chromogenic substrate. Examples of suitable enzymes include, but are not limited to, urease, alkaline phosphatase, (horseradish) hydrogen peroxidase, or glucose oxidase. Preferred secondary binding ligands are biotin and / or avidin and streptavidin compounds. The use of such labels is well known to those skilled in the art and is described, for example, in U.S. Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241; each of which is incorporated herein by reference. Molecules containing azide groups may also be used to form covalent bonds with proteins through reactive nitrene intermediates generated by low intensity ultraviolet light (Potter & Haley, 1983).
[0236] In some aspects, immunoconjugates are contemplated, including an antibody or antigen-binding fragment thereof conjugated to a cytotoxic agent, such as a chemotherapeutic agent, a drug, a growth inhibitory agent, a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or a fragment thereof), or a radioactive isotope (i.e., a radioconjugate). In this way, the agent of interest can be directly targeted to cells bearing the cell surface antigen. The antibody and agent can be associated through non-covalent interactions, such as electrostatic forces, or by covalent bonding. Various linkers known in the art can be used to form immunoconjugates. In addition, the immunoconjugate can be provided in the form of a fusion protein. In one aspect, the antibody can be conjugated to various therapeutic agents to target cell surface antigens. Examples of conjugated agents include, but are not limited to, metal chelate complexes, drugs, toxins, and other effector molecules, such as cytokines, lymphokines, chemokines, immunomodulators, radiosensitizers, asparaginase, carboranes, and radioactive halogens.
[0237] In antibody-drug conjugates (ADCs), an antibody (Ab) is conjugated to one or more drug moieties (D) through a linker (L). ADCs can be prepared by several routes using organic chemistry reactions, conditions, and reagents known to those skilled in the art, including: (1) reacting a nucleophilic group on an antibody with a bivalent linker reagent to form Ab-L via a covalent bond, followed by reaction with a drug moiety, D; and (2) reacting a nucleophilic group on a drug moiety with a bivalent linker reagent to form DL via a covalent bond, followed by reaction with a nucleophilic group on an antibody. Antibody-drug conjugates can also be produced by modifying an antibody to introduce an electrophilic moiety that can react with a nucleophilic substituent on the linker reagent or drug. Alternatively, a fusion protein containing the antibody and cytotoxic agent can be produced, for example, by recombinant techniques or peptide synthesis. The length of DNA can include regions encoding the two portions of the conjugate, either adjacent to each other or separated by a region encoding a linker peptide that does not disrupt the desired properties of the conjugate. In yet another aspect, antibodies may be conjugated to a "receptor" (such as streptavidin) for use in tumor or cancer cell pretargeting, where the antibody-receptor conjugate is administered to a patient, followed by removal of unbound conjugate from the circulation using a clearing agent, and then administration of a "ligand" (e.g., avidin) conjugated to a cytotoxic agent (e.g., a radionucleotide).
[0238] Examples of antibody-drug conjugates known to those skilled in the art are prodrugs useful for local delivery of cytotoxic or cytostatic agents, i.e., drugs to kill or inhibit tumor cells in the treatment of cancer (Syrigos and Epenetos, Anticancer Res. 19:605-614 (1999); Niculescu-Duvaz and Springer, Adv. Drg. Del. Rev. 26:151-172 (1997); U.S. Pat. No. 4,975,278). In contrast, systemic administration of these unconjugated drugs can result in unacceptable levels of toxicity to both normal cells and target tumor cells (Baldwin et al., Lancet 1:603-5 (1986); Thorpe, (1985) "Antibody Carriers of Cytotoxic Agents in Cancer Therapy: A Review," In: Monoclonal Antibodies '84: Biological and Clinical Applications, A. Pincera et al., (eds.) pp. 475-506). Both polyclonal and monoclonal antibodies have been reported to be useful in these strategies (Rowland et al., Cancer Immunol. Immunother. 21:183-87 (1986)).
[0239] In certain aspects, ADCs comprise covalent or aggregate conjugates of antibodies or antigen-binding fragments thereof with other proteins or polypeptides, such as by expression of recombinant fusion proteins containing heterologous polypeptides fused to the N- or C-terminus of the antibody polypeptide. For example, the conjugated peptide can be a heterologous signal (or leader) polypeptide, such as the yeast alpha-factor leader, or a peptide such as an epitope tag (e.g., V5-His). Antibody-containing fusion proteins can also contain peptides (e.g., poly-His) added to facilitate antibody purification or identification. Antibody polypeptides can also be linked to a FLAG® (Sigma-Aldrich, St. Louis, Mo.) peptide, as described in Hopp et al., Bio / Technology 6:1204 (1988) and U.S. Patent No. 5,011,912. Oligomers containing one or more antibody polypeptides can be used as antagonists. Oligomers can be in the form of covalently or non-covalently linked dimers, trimers, or higher-order oligomers. Oligomers containing two or more antibody polypeptides are contemplated for use. Other oligomers include heterodimers, homotrimers, heterotrimers, homotetramers, heterotetramers, etc. In certain aspects, oligomers contain multiple antibody polypeptides linked via covalent or non-covalent interactions between peptide moieties fused to the antibody polypeptides. Such peptides can be peptide linkers (spacers) or peptides with oligomerization-promoting properties. As described in more detail below, antibody-derived leucine zippers and certain polypeptides are among the peptides that can promote oligomerization of attached antibody polypeptides.
[0240] b. Conjugation Methodology Several methods for attaching or conjugating antibodies to their conjugate moieties are known in the art.Some attachment methods involve the use of metal chelate complexes, for example, diethylenetriaminepentaacetic anhydride (DTPA); ethylenetriaminetetraacetic acid; N-chloro-p-toluenesulfonamide; and / or organic chelating agents such as tetrachloro-3-6-diphenylglycouril-3 (U.S. Patent Nos. 4,472,509 and 4,938,948, each of which is incorporated herein by reference) attached to antibodies.Monoclonal antibodies can also be reacted with enzymes in the presence of coupling agents such as glutaraldehyde or periodate. Conjugates can also be prepared using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). In some aspects, derivatization of immunoglobulins by selectively introducing sulfhydryl groups into the Fc region of the immunoglobulin using reaction conditions that do not alter the antibody binding site is contemplated. Antibody conjugates produced according to this methodology have been disclosed to exhibit improved longevity, specificity, and sensitivity (U.S. Pat. No. 5,196,066, incorporated herein by reference). Site-specific attachment of effector or reporter molecules has also been disclosed in the literature, in which the reporter or effector molecule is conjugated to carbohydrate residues in the Fc region (O'Shannessy et al., 1987).
[0241] II. Antibody production A. Antibody Production Methods for preparing and characterizing antibodies for use in diagnostic and detection assays, for purification, and for use as therapeutic agents are well known in the art, as disclosed, for example, in U.S. Patent Nos. 4,011,308; 4,722,890; 4,016,043; 3,876,504; 3,770,380; and 4,372,745 (see, e.g., "Antibodies: A Laboratory Manual," Cold Spring Harbor Laboratory, 1988; incorporated herein by reference). These antibodies may be polyclonal or monoclonal antibody preparations, monospecific antisera, human antibodies, hybrid or chimeric antibodies, such as humanized antibodies, altered antibodies, F(ab')2 fragments, Fab fragments, Fv fragments, single-domain antibodies, dimeric or trimeric antibody fragment constructs, minibodies, or functional fragments thereof that bind to the antigen of interest. In certain aspects, polypeptides, peptides, and proteins, as well as immunogenic fragments thereof, for use in various embodiments can be synthesized in solution or on a solid support according to conventional techniques. See, e.g., Stewart and Young, (1984); Tarn et al., (1983); Merrifield, (1986); and Barany and Merrifield (1979), each of which is incorporated herein by reference.
[0242] Briefly, polyclonal antibodies are prepared by immunizing an animal with an antigen or a portion thereof and collecting antisera from the immunized animal. The antigen may be altered compared to the antigen sequence found in nature. In some embodiments, variant or altered antigenic peptides or polypeptides are used to generate antibodies. An inoculum is typically prepared by dispersing the antigen composition in a physiologically tolerable diluent to form an aqueous composition. Antisera are then collected by methods known in the art, and the serum can be used directly for various purposes, or the desired antibody fraction can be purified by well-known methods such as affinity chromatography (Harlow and Lane, Antibodies: A Laboratory Manual 1988).
[0243] Methods for producing monoclonal antibodies are also well known in the art (Kohler and Milstein, 1975; Harlow and Lane, 1988; U.S. Patent 4,196,265, incorporated herein by reference in its entirety for all purposes). Typically, this technique involves immunizing a suitable animal with a selected immunogenic composition, such as a purified or partially purified protein, polypeptide, peptide, or domain. The resulting antibody-producing B cells from the immunized animal, or all dissociated spleen cells, are then induced to fuse with cells from an immortalized cell line to form hybridomas. Myeloma cell lines suitable for use in hybridoma-producing fusion procedures are preferably non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that subsequently render them incapable of growth in certain selective media and support the growth of only the desired fused cells (hybridomas). Typically, the fusion partner contains properties that allow for selection of the resulting hybridomas using a specific medium. For example, the fusion partner can be hypoxanthine / aminopterin / thymidine (HAT) sensitive. Methods for generating hybrids of antibody-producing spleen or lymph node cells and myeloma cells typically involve mixing somatic cells with myeloma cells in the presence of one or more agents (chemical or electrical) that promote cell membrane fusion. Hybridoma selection can then be performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing individual clonal supernatants (after 2-3 weeks) for the desired reactivity. Fusion procedures, immunization protocols, and techniques for isolating immunized spleen cells for fusion to produce hybridomas are known in the art.
[0244] Other techniques for producing monoclonal antibodies include viral or oncogenic transformation of B-lymphocytes, molecular cloning approaches that can be used to generate nucleic acids or polypeptides, the selected lymphocyte antibody method (SLAM) (see, e.g., Babcook et al., Proc. Natl. Acad. Sci. USA 93:7843-7848 (1996)), preparation of combinatorial immunoglobulin phagemid libraries from RNA isolated from the spleens of immunized animals and selection of phagemids that express the appropriate antibody, or production of cells that express antibodies from the genomic sequence of cells containing engineered immunoglobulin loci using Cre-mediated site-specific recombination (see, e.g., US 6,091,001).
[0245] Monoclonal antibodies can be further purified using various chromatographic methods, such as filtration, centrifugation, and HPLC or affinity chromatography. Monoclonal antibodies can be further screened or optimized for specificity, avidity, half-life, immunogenicity, on-binding, off-binding properties, or overall functional properties relative to the treatment of infection. Thus, monoclonal antibodies can have alterations in the amino acid sequence of the CDRs, including insertions, deletions, or substitutions of conserved or non-conserved amino acids.
[0246] The immunogenicity of certain immunogen compositions can be enhanced by the use of non-specific stimulators of the immune response known as adjuvants. Adjuvants that can be used according to various embodiments include, but are not limited to, IL-1, IL-2, IL-4, IL-7, IL-12, -interferon, GMCSP, BCG, aluminum hydroxide, MDP compounds such as thur-MDP and nor-MDP, CGP (MTP-PE), lipid A, and monophosphoryl lipid A (MPL). Exemplary adjuvants can include complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed Mycobacterium tuberculosis), incomplete Freund's adjuvant, and / or aluminum hydroxide adjuvant. In addition to adjuvants, it may be desirable to co-administer biological response modifiers (BRMs), including but not limited to cimetidine (CIM; 1200 mg / d) (Smith / Kline, PA); low-dose cyclophosphamide (CYP; 300 mg / m2) (Johnson / Mead, NJ), cytokines such as beta-interferon, IL-2, or IL-12, or genes encoding proteins involved in immune helper function; for example, the B-7.A phage display system can be used to expand the antibody molecule population in vitro. Saiki, et al., Nature 324:163 (1986);Scharf et al., Science 233:1076 (1986);U.S. Pat. Enzymol. (1995) 8:94; Barbas, III et al., Proc Natl Acad Sci USA 88:7978 (1991).
[0247] B. Fully Human Antibody Production Methods for producing fully human antibodies are available. The use of fully human antibodies can minimize immunogenicity and allergic reactions that can be caused by administering nonhuman monoclonal antibodies to humans as therapeutic agents. In one embodiment, human antibodies can be produced in nonhuman transgenic animals, such as transgenic mice capable of producing human antibodies of multiple isotypes against proteins (e.g., IgG, IgA, and / or IgE) by undergoing VDJ recombination and isotype switching. Thus, this aspect applies not only to antibodies, antibody fragments, and pharmaceutical compositions thereof, but also to nonhuman transgenic animals, B cells, host cells, and hybridomas that produce monoclonal antibodies. Applications of human antibodies include, but are not limited to, detection of cells expressing the predicted protein either in vivo or in vitro, pharmaceutical preparations containing the antibodies of the present invention, and methods of treating disorders by administering the antibodies.
[0248] Fully human antibodies can be produced by immunizing transgenic animals (usually mice) that are capable of producing a repertoire of human antibodies in the absence of endogenous immunoglobulin production. Antigens for this purpose typically have six or more contiguous amino acids and are optionally conjugated to a carrier such as a hapten. See, for example, Jakobovits et al., Proc. Natl. Acad. Sci. USA 90:2551-2555 (1993); Jakobovits et al., Nature 362:255-258 (1993); Bruggermann et al., Year in Immunol. 7:33 (1993). In one example, transgenic animals are produced by disabling the endogenous mouse immunoglobulin loci encoding mouse heavy and light immunoglobulin chains therein and inserting large fragments of human genomic DNA containing loci encoding human heavy and light chain proteins into the mouse genome. The partially modified animals with less than complete human immunoglobulin locus components are then crossbred to obtain animals with all of the desired immune system modifications. When administered an immunogen, these transgenic animals produce antibodies that are immunospecific to the immunogen but have human, rather than mouse, amino acid sequences, including the variable regions. For further details of such methods, see, for example, International Patent Application Publication Nos. WO 96 / 33735 and WO 94 / 02602, which are incorporated herein by reference in their entireties. Additional methods involving transgenic mice for producing human antibodies are described in U.S. Pat. Nos. 5,545,807; 6,713,610; 6,673,986; 6,162,963; 6,300,129; 6,255,458; 5,877,397; 5,874,299 and 5,545,806; International Patent Application Publication Nos. WO 91 / 10741 and WO 90 / 04036; and European Patent Nos. EP 546073B1 and EP 546073A1, all of which are incorporated by reference in their entireties for all purposes.
[0249] The above-described transgenic mice, referred to herein as "HuMAb" mice, contain human immunoglobulin gene minilocuses encoding unrearranged human heavy chain (μ and γ) and κ light chain immunoglobulin sequences, along with targeted mutations that inactivate the endogenous μ and κ chain loci (Lonberg et al., Nature 368:856-859 (1994)). Thus, the mice exhibit reduced expression of mouse IgM or κ chains, and in response to immunization, the introduced human heavy and light chain transgenes undergo class switching and somatic mutation to produce high-affinity human IgG κ monoclonal antibodies (Lonberg et al., supra; Lonberg and Huszar, Intern. Ref. Immunol. 13:65-93 (1995); Harding and Lonberg, Ann. NY Acad. Sci. 764:536-546 (1995)). Preparation of HuMAb mice was carried out as described by Taylor et al., Nucl. Acids Res. 20:6287-6295 (1992); Chen et al., Int. Immunol. 5:647-656 (1993); Tuaillon et al., J. Immunol. 152:2912-2920 (1994); Lonberg et al., supra; Lonberg, Handbook of Exp. Pharmacol. 113:49-101 (1994); Taylor et al., Int. Immunol. 6:579-591 (1994); Lonberg and Huszar, Intern. Ref. Immunol. 13:65-93 (1995); Harding and Lonberg, Ann. NY Acad. Sci. 764:536-546 (1995); Fishwild et al. al., Nat. Biotechnol. 14:845-851 (1996); the foregoing references are incorporated herein by reference in their entireties for all purposes.See also U.S. Patent Nos. 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,789,650; 5,877,397; 5,661,016; 5,814,318; 5,874,299; 5,770,429; and 5,545,807; and International Patent Application Publication Nos. WO 93 / 1227; WO 92 / 22646; and WO 92 / 03918, the disclosures of all of which are incorporated herein by reference in their entireties for all purposes. Techniques utilized to produce human antibodies in these transgenic mice are also disclosed in WO 98 / 24893 and Mendez et al., Nat. Genetics 15:146-156 (1997), which are incorporated herein by reference. For example, the HCo7 and HCo12 transgenic mouse strains can be used to generate human antibodies.
[0250] Using hybridoma technology, antigen-specific humanized monoclonal antibodies with desired specificity can be produced and selected from transgenic mice such as those described above. Such antibodies can be cloned and expressed using suitable vectors and host cells, or antibodies can be collected from cultured hybridoma cells. Fully human antibodies can also be derived from phage display libraries (as disclosed in Hoogenboom et al., J. Mol. Biol. 227:381 (1991); and Marks et al., J. Mol. Biol. 222:581 (1991)). One such technique is described in International Patent Application Publication No. WO 99 / 10494 (incorporated herein by reference), which describes the isolation of high-affinity and functional agonistic antibodies against MPL and msk receptors using such an approach.
[0251] C. Antibody Fragment Production Antibody fragments that retain the ability to recognize the antigen of interest will also be useful herein.A large number of antibody fragments are known in the art, which contain antigen-binding sites that can exhibit the immunological binding characteristics of intact antibody molecules, and can then be modified by methods known in the art.Functional fragments that contain only the variable regions of heavy and light chains can also be produced using standard techniques, such as recombinant production or preferential proteolytic cleavage of immunoglobulin molecules.These fragments are known as Fv.See, for example, Inbar et al., Proc. Nat. Acad. Sci. USA 69:2659-2662 (1972); Hochman et al., Biochem. 15:2706-2710 (1976); and Ehrlich et al., Biochem. 19:4091-4096 (1980).
[0252] Single-chain variable fragments (scFvs) can be prepared by fusing DNA encoding a peptide linker between DNA encoding two variable domain polypeptides (VL and VH). Depending on the length of the flexible linker between the two variable domains, scFvs can form antigen-binding monomers, or they can form multimers (e.g., dimers, trimers, or tetramers) (Kortt et al., Prot. Eng. 10:423 (1997); Kort et al., Biomol. Eng. 18:95-108 (2001)). By combining polypeptides containing different VL and VH, multimeric scFvs that bind to different epitopes can be formed (Kriangkum et al., Biomol. Eng. 18:31-40 (2001)). Antigen-binding fragments are typically produced by recombinant DNA methods known to those skilled in the art. Although the two domains of an Fv fragment, VL and VH, are encoded by separate genes, they can be joined by a synthetic linker, allowing them to be produced as a single-chain polypeptide using recombinant techniques (known as a single-chain Fv (sFv or scFv); see, e.g., Bird et al., Science 242:423-426 (1988); and Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988)). Design criteria include determining an appropriate length spanning the distance between the C-terminus of one chain and the N-terminus of the other, where the linker is generally formed from small, hydrophilic amino acid residues that do not tend to coil or form secondary structures. Suitable linkers generally comprise polypeptide chains of alternating pairs of glycine and serine residues and may contain glutamic acid and lysine residues inserted to enhance solubility. Antigen-binding fragments are screened for utility in the same manner as intact antibodies. Such fragments include those obtained by amino- and / or carboxy-terminal deletions, but in which the remaining amino acid sequence is substantially identical to the corresponding positions in the naturally occurring sequence as deduced, for example, from the full-length cDNA sequence.
[0253] Antibodies can also be generated using peptide analogs of the epitopic determinants disclosed herein, which can consist of non-peptide compounds with properties similar to those of the template peptide. These types of non-peptide compounds are called "peptide mimetics" or "peptidomimetics." Fauchere, J. Adv. Drug Res. 15:29 (1986); Veber and Freidinger TINS p. 392 (1985); and Evans et al., J. Med. Chem. 30:1229 (1987). Liu et al. (2003) also described "antibody-like binding peptidomimetics" (ABiPs), which are peptides that act as paired-down antibodies and have certain advantages, such as longer serum half-lives and easier synthesis. These analogs can be peptides, non-peptides, or combinations of peptide and non-peptide regions. Fauchere, Adv. Drug Res. 15:29 (1986); Veber and Freidiner, TINS p. 392 (1985); and Evans et al., J. Med. Chem. 30:1229 (1987), the entire contents of which are incorporated by reference herein for all purposes. Peptide mimetics structurally similar to therapeutically useful peptides may be used to provide similar therapeutic or prophylactic effects. Such compounds are often developed with the aid of computerized molecular modeling. Generally, the peptidomimetics of the present invention are proteins structurally similar to antibodies that exhibit desired biological activity, such as the ability to bind to proteins, but with one or more peptide linkages optionally substituted by linkages selected from -CHNH-, -CHS-, -CH-CH-, -CH=CH- (cis and trans), -COCH-, -CH(OH)CH-, and -CHSO-, using methods well known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) may be used in certain embodiments of the invention to generate more stable proteins.Additionally, constrained peptides containing the consensus sequence or substantially identical consensus sequence variants may be generated by methods known in the art, for example, by adding internal cysteine residues capable of forming intramolecular disulfide bridges that cyclize the peptide (Rizo and Gierasch, Ann. Rev. Biochem. 61:387 (1992), incorporated herein by reference).
[0254] Once generated, the phage display library can be used to improve the immunological binding affinity of the Fab molecules using known techniques. See, for example, Figini et al., J. Mol. Biol. 239:68 (1994). The coding sequences for the heavy and light chain portions of the Fab molecules selected from the phage display library can be isolated or synthesized and cloned into any suitable vector or replicon for expression. Any suitable expression system can be used.
[0255] III. Obtaining the encoded antibody In some aspects, nucleic acid molecules encode antibody polypeptides (e.g., heavy or light chains, variable domains only, or full length), which may be produced by methods known in the art, for example, isolated from B cells of immunized mice and isolated by phage display, expressed in any suitable recombinant expression system, and assembled to form antibody molecules.
[0256] A. Expression The nucleic acid molecules may be used to express large amounts of recombinant antibodies or to produce chimeric antibodies, single-chain antibodies, immunoadhesins, diabodies, mutated antibodies, and other antibody derivatives. If the nucleic acid molecules are derived from a non-human, non-transgenic animal, the nucleic acid molecules may be used for antibody humanization.
[0257] 1. Vector In some aspects, expression vectors containing nucleic acid molecules encoding a polypeptide of a desired sequence or a portion thereof (e.g., a fragment containing one or more CDRs or one or more variable region domains) are contemplated. Expression vectors containing nucleic acid molecules may encode heavy chains, light chains, or antigen-binding portions thereof. In some aspects, expression vectors containing nucleic acid molecules may encode fusion proteins, modified antibodies, antibody fragments, and probes thereof. In addition to control sequences governing transcription and translation, vectors and expression vectors may further contain nucleic acid sequences that perform other functions.
[0258] To express an antibody or its antigen-binding fragment, DNA encoding partial or full-length light and heavy chains is inserted into an expression vector so that the gene regions are operably linked to transcriptional and translational control sequences. In some aspects, vectors encoding functionally complete human CH or CL immunoglobulin sequences have been engineered with appropriate restriction sites so that any VH or VL sequence can be easily inserted and expressed. Typically, expression vectors used in any host cell contain sequences for plasmid or viral maintenance and sequences for cloning and expressing exogenous nucleotide sequences. Such sequences, collectively referred to as "flanking sequences," typically include one or more of the following operably linked nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcription termination sequence, a complete intron sequence containing donor and acceptor splice sites, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for inserting a nucleic acid encoding a polypeptide to be expressed, and a selectable marker element. Such sequences and methods for using them are well known in the art.
[0259] 2. Expression system Numerous expression systems exist that contain at least some or all of the expression vectors discussed above. Prokaryotic and / or eukaryotic systems can be used with certain embodiments to produce nucleic acid sequences or their cognate polypeptides, proteins, and peptides. Commercially and widely available systems include, but are not limited to, bacterial, mammalian, yeast, and insect cell systems. A variety of different host cells have characteristic and specific mechanisms for post-translational processing and modification of proteins. An appropriate cell line or host system can be selected to ensure the correct modification and processing of the expressed foreign protein. Those skilled in the art can use an appropriate expression system to express the vector to produce the nucleic acid sequence or its cognate polypeptide, protein, or peptide.
[0260] 3. Gene transfer method Suitable methods of nucleic acid delivery to achieve expression of the compositions are expected to include virtually any method by which nucleic acid (e.g., DNA, including viral and non-viral vectors) can be introduced into a cell, tissue, or organism, as described herein or known to those of skill in the art. Such methods include by injection (U.S. Patents 5,994,624, 5,981,274, 5,945,100, 5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466, and 5,580,859, each of which is incorporated herein by reference), microinjection (Harland and Weintraub, 1985; U.S. Patent 5,789,215, incorporated herein by reference); by electroporation (U.S. Patent No. 5,384,253, incorporated herein by reference); by calcium phosphate precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987; Rippe et al., 1990); by the use of DEAE-dextran followed by polyethylene glycol (Gopal, 1985); by direct sonic loading (Fechheimer et al., 1987); by liposome-mediated transfection (Nicolau and Sene, 1982; Fraley et al., 1979; Nicolau et al., 1987; Wong et al., 1980; Kaneda et al., 1989; Kato et al., 1991); by particle bombardment (PCT Application Nos. WO 94 / 09699 and 95 / 06128; U.S. Patents 5,610,042; 5,322,783; 5,563,055; 5,550,318; 5,538,877; and 5,538,880, each of which is incorporated herein by reference); by agitation with silicon carbide fibers (Kaeppler et al.These methods include, but are not limited to, direct delivery of DNA, such as by Agrobacterium-mediated transformation (U.S. Patents 5,591,616 and 5,563,055, each incorporated herein by reference); or by PEG-mediated transformation of protoplasts (Omirulleh et al., 1993; U.S. Patents 4,684,611 and 4,952,500, each incorporated herein by reference); or by desiccation / inhibition-mediated DNA uptake (Potrykus et al., 1985). Other methods include gene transfer by viral transduction, e.g., lentiviral or retroviral transduction.
[0261] 4. Host cells Another aspect is the use of host cells into which a recombinant expression vector has been introduced. Antibodies can be expressed in a variety of cell types. Antibody-encoding expression constructs can be transfected into cells using a variety of methods known in the art. Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. Some vectors may employ regulatory sequences that enable replication and / or expression in both prokaryotic and eukaryotic cells. In certain aspects, antibody expression constructs can be placed under the control of promoters associated with T cell activation, such as promoters controlled by NFAT-1 or NF-κB, both of which are transcription factors that can be activated upon T cell activation. Controlling antibody expression allows T cells, such as tumor-targeting T cells, to sense their surroundings and perform real-time modulation of cytokine signaling, both in themselves and in surrounding endogenous immune cells. Those skilled in the art will understand the conditions for incubating and maintaining host cells and allowing vector replication. Also understood and known are techniques and conditions that allow for the large-scale production of vectors and the production of nucleic acids encoded by the vectors and their cognate polypeptides, proteins, or peptides.
[0262] It is known that for the stable transfection of mammalian cells, depending on the expression vector and transfection technique used, only a small number of cells can integrate foreign DNA into their genome.In order to identify and select these integrants, a selection marker (for example, for antibiotic resistance) is generally introduced into host cells together with the gene of interest.The cells that have been stably transfected with introduced nucleic acid can be identified by drug selection, among other methods known in the art (for example, the cells that have integrated the selection marker gene will survive, while other cells will die).
[0263] B. Isolation Nucleic acid molecules encoding either or both of the entire heavy and light chains or their variable regions of an antibody can be obtained from any source that produces antibodies. Methods for isolating mRNA encoding an antibody are well known in the art. See, for example, Sambrook et al. (supra). The sequences of human heavy and light chain constant region genes are also known in the art. See, for example, Kabat et al., 1991 (supra). The nucleic acid molecules encoding the full-length heavy and / or light chains can then be expressed from cells into which they have been introduced, and the antibody can be isolated.
[0264] IV. Viruses Aspects of the present disclosure relate to the treatment, analysis, or use of viruses. In some embodiments, methods for treating or preventing viral infections are disclosed. In some embodiments, compositions comprising one or more antiviral agents are disclosed. In some embodiments, methods for diagnosing viral infections are disclosed. In some embodiments, methods for detecting viruses in samples are disclosed.
[0265] A. Coronavirus In certain embodiments, the virus is from the Coronaviridae family. The Coronaviridae family is a family of enveloped, positive-sense, single-stranded RNA viruses. Coronavirus is the common name for the Coronaviridae family and the Orthocoronavirus subfamily (also called the Coronavirinae subfamily). The Coronaviridae family is organized into two subfamilies, five genera, 23 subgenera, and approximately 40 species. These are enveloped viruses with a positive-sense, single-stranded RNA genome and a nucleocapsid with helical symmetry. Coronavirus genome sizes range from approximately 26 to 32 kilobases.
[0266] The present disclosure encompasses the treatment or prevention of infection by any virus in the Coronaviridae family. In certain embodiments, the present disclosure encompasses the treatment or prevention of infection by any virus in the Coronavirinae subfamily, which includes the four genera Alpha, Beta, Gamma, and Deltacoronavirus. In specific embodiments, the present disclosure encompasses the treatment or prevention of infection by any virus in the genus Betacoronavirus, which includes the subgenus Sarbecovirus and includes the species Severe Acute Respiratory Syndrome-Associated Coronavirus. In specific embodiments, the present disclosure encompasses the treatment or prevention of infection by any virus in the species Severe Acute Respiratory Syndrome-Associated Coronavirus, including the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19) strains. The present disclosure encompasses the treatment or prevention of infection with any isolate, strain, type (including types A, B, and C; Forster et al., 2020, PNAS, available on the World Wide Web at doi.org / 10.1073 / pnas.2004999117), cluster, or subcluster of the species of severe acute respiratory syndrome-associated coronavirus, including at least SARS-CoV-2. In specific embodiments, the virus has a genome length of 29,000-30,000, 29,100-29,900, 29,200-29,900, 29,300-29,900, 29,400-29,900, 29,500-29,900, 29,600-29,900, 29,700-29,900, 29,800-29,900, or 29,780-29,900 base pairs in length.
[0267] Examples of specific SARS-CoV-2 viruses include those listed in the NCBI GenBank® Database, and these GenBank® accession sequences are incorporated herein by reference in their entireties: (a) LC534419, LC534418, LC528233, and LC529905 (examples of different lineages from Japan); (b) MT281577, MT226610, NC_045512, MN996531, and MN908947 (examples of different lineages from China); (c) MT281530 (Iran); (d) MT126808 (Brazil); (e) MT020781 (Finland); (f) MT093571 (Sweden); (g) MT263074 (Peru); (h) MT292582 and MT292581 and MT292580 and MT292579 (examples of different lineages from Spain); (i) examples from the United States, e.g., MT276331 (TX); MT276330 (FL); MT276328 (OR) MT276327 (GA); MT276325 (WA); MT276324 (CA); MT276323 (RI); MT188341 (MN); and (j) MT276598 (Israel). In certain aspects, the present disclosure encompasses the treatment or prevention of infection by any of these or similar viruses, including viruses whose genomes share at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, or 99.9% identity to any of these viruses. In certain aspects, the present disclosure encompasses the treatment or prevention of infection by any of these or similar viruses, including viruses whose genomes have an entire sequence that is greater than 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, or 99.9% identical to any of these viruses.As one specific example, the present disclosure includes methods for the treatment or prevention of infection with the virus having the genomic sequence represented by GenBank® Accession No. NC_045512 (originating from Wuhan, China), and any virus having a genomic sequence having at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, or 99.9% identity to the genomic sequence represented by GenBank® Accession No. NC_045512.
[0268] SARS-CoV-2 proteins are described in detail, for example, in Yoshimoto FK (2020). The protein journal, 39(3), 198-216, which is incorporated herein by reference in its entirety.
[0269] V. Antibodies, Antigen-Binding Fragments, and Polypeptides As used herein, "protein" or "polypeptide" refers to a molecule containing at least five amino acid residues. As used herein, the term "wild-type" refers to the endogenous version of a molecule that occurs naturally in an organism. While in some embodiments, a wild-type version of a protein or polypeptide is used, in many embodiments of the present disclosure, a modified protein or polypeptide is used to generate an immune response. The above terms may be used interchangeably. A "modified protein" or "modified polypeptide" or "variant" refers to a protein or polypeptide whose chemical structure, particularly its amino acid sequence, has been altered relative to the wild-type protein or polypeptide. In some embodiments, a modified / variant protein or polypeptide has at least one modified activity or function (recognizing that a protein or polypeptide may have multiple activities or functions). It is specifically contemplated that a modified / variant protein or polypeptide may be altered with respect to one activity or function but still retain wild-type activity or function in other respects, such as immunogenicity. The term polypeptide also includes antibody fragments as well as antibody domains described herein, such as HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, HFRW1, HFRW2, HFRW3, HFRW4, LFRW1, LFRW2, LFRW3, LFRW4, VH, VL, CH, or CL.
[0270] When a protein is specifically mentioned herein, it generally refers to a natural (wild-type) or recombinant (modified) protein, or a protein that, optionally, has any signal sequence removed. Proteins can be isolated directly from the organism in which they occur, produced by recombinant DNA / exogenous expression methods, or produced by solid-phase peptide synthesis (SPPS) or other in vitro methods. In certain embodiments, there are isolated nucleic acid segments and recombinant vectors incorporating nucleic acid sequences encoding polypeptides (e.g., antibodies or fragments thereof). The term "recombinant" can be used in reference to a polypeptide or the name of a specific polypeptide, but generally refers to a polypeptide produced from a nucleic acid molecule that has been manipulated in vitro or is the product of replication of such a molecule.
[0271] In certain embodiments, the size of an antibody, antigen-binding fragment, protein, or polypeptide (wild type or modified) is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375 , 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1100, 1200, 1300, 1400, 1500, 1750, 2000, 2250, 2500 amino acid residues or more, and any range derivable therein, or derivatives of the corresponding amino acid sequences described or referenced herein. It is contemplated that polypeptides may be mutated by truncation so as to be shorter than their corresponding wild-type forms, and they may also be altered by fusion or conjugation with heterologous protein or polypeptide sequences having a particular function (e.g., for targeting or localization, for enhanced immunogenicity, for purification purposes, etc.) As used herein, the term "domain" refers to any distinct function or structural unit of a protein or polypeptide, and generally refers to a sequence of amino acids having a structure or function recognizable to one of skill in the art.
[0272] An antibody, antigen-binding fragment, polypeptide, protein, or polynucleotide encoding such a polypeptide or protein of the disclosure can include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (or any derivable range therein) or more variant amino acid or nucleic acid substitutions of SEQ ID NOs: 1-2812, or NO: 1 to 2812 at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 1 3, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157 , 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 300, 400, 500, 550, 1000 or more, or a maximum of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, 550, 1000 or more, or a maximum of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 22, 23, 24, 25, 30, 40, 50, 550, 1000 or more, or a maximum of 3 1, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94 ,95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 1 27, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 8, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189 , 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220,221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 300, 400, 500, 550, 1000 or more contiguous amino acids or nucleic acids, or any derivable range therein, and at least 60%, 61%, It may be 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any derivable range therein) similar, identical, or homologous.
[0273] In some embodiments, the antibody, antigen-binding fragment, protein, or polypeptide has the sequence of SEQ ID NO: NO:1-2812 amino acids 1-2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 8, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184 43, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202 2, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261,262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、 501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966、967、968、969、970、971、972、973、974、975、976、977、978、979、980、981、982、983、984、985、986、987、988、989、990、991、992、993、994、995、996、997、998、999、or 1000 (or any derivable range therein).
[0274] In some embodiments, the antibody, antigen-binding fragment, or polypeptide has the sequence of SEQ ID NO: NO: 1 to 2812 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 8 0, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 1 45, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264,265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、 501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966、967、968、969、970、971、972、973、974、975、976、977、978、979、980、981、982、983、984、985、986、987、988、989、990、991、992、993、994、995、996、997、998、999、or 1000 (or any derivable range therein) contiguous amino acids or nucleic acids.
[0275] In some embodiments, the antibody, antigen-binding fragment, protein, or polypeptide has at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 1109%, 1110%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135%, 136%, 137%, 138%, 139%, 140%, 141%, 142%, 143%, 144%, 145%, 146%, 147%, 148%, 149%, 150%, 151%, 152%, 153%, 154%, 155%, 156%, 157%, 158%, 159%, 160%, 161%, 162%, 163%, 164%, 165%, %, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, up to 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. 3%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, or exactly 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. 5%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% (or any derivable range therein) similar, identical, or homologous to a SEQ ID NO: 1 to 2812 at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 1 1, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117,118、119、120、121、122、123、124、125、126、127、128、129、130、131、132、133、134、135、136、137、138、139、140、141、142、143、144、145、146、147、148、149、150、151、152、153、154、155、156、157、158、159、160、161、162、163、164、165、166、167、168、169、170、171、172、173、174、175、176、177、178、179、180、181、182、183、184、185、186、187、188、189、190、191、192、193、194、195、196、197、198、199、200、201、202、203、204、205、206、207、208、209、210、211、212、213、214、215、216、217、218、219、220、221、222、223、224、225、226、227、228、229、230、231、232、233、234、235、236、237、238、239、240、241、242、243、244、245、246、247、248、249、250、251、252、253、254、255、256、257、258、259、260、261、262、263、264、265、266、267、268、269、270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、 501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966、967、968、969、970、971、972、973、974、975、976、977、978、979、980、981、982、983、984、985、986、987、988、989、990、991、992、993、994、995、996、997、998、999、Or 1000, Up to 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 4, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 , 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 1 83, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214 4, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 , 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276,277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、 501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966、967、968、969、970、971、972、973、974、975、976、977、978、979、980、981、982、983、984、985、986、987、988、989、990、991、992、993、994、995、996、997、998、999、Or 1000, or Exactly 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 4, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120 , 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 1 83, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214 4, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245 , 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276,277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、 501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966、967、968、969、970、971、972、973、974、975、976、977、978、979、980、981、982、983、984、985、986、987、988、989、990、991、992、993、994、995、996、997、998、999、or 1000 (or any derivable range therein) contiguous amino acids or nucleic acids.
[0276] In some cases, the SEQ ID NO: 1 to 2812, any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 ,81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 1 16, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177 , 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 20 8, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 2 39, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269,270、271、272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、 501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966、967、968、969、970、971、972、973、974、975、976、977、978、979、980、981、982、983、984、985、986、987、988、989、990、991、992、993、994、995、996、997、998、999、Or starting from 1000th place, and At least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80 of any of SEQ ID NOs: 1 to 2812 , 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116 6, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147 , 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178 , 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209 , 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240 ,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255,256,257,258,259,260,261,262,263,264,265,266,267,268,269,270,271,272、273、274、275、276、277、278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、 501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966、967、968、969、970、971、972、973、974、975、976、977、978、979、980、981、982、983、984、985、986、987、988、989、990、991、992、993、994、995、996、997、998、999、Or 1000, Up to 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 5, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 1, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152 , 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 15, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246 6, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277,278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、 501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966、967、968、969、970、971、972、973、974、975、976、977、978、979、980、981、982、983、984、985、986、987、988、989、990、991、992、993、994、995、996、997、998、999、Or 1000, or Exactly 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 5, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121 1, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152 , 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 15, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246 6, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277,278、279、280、281、282、283、284、285、286、287、288、289、290、291、292、293、294、295、296、297、298、299、300、301、302、303、304、305、306、307、308、309、310、311、312、313、314、315、316、317、318、319、320、321、322、323、324、325、326、327、328、329、330、331、332、333、334、335、336、337、338、339、340、341、342、343、344、345、346、347、348、349、350、351、352、353、354、355、356、357、358、359、360、361、362、363、364、365、366、367、368、369、370、371、372、373、374、375、376、377、378、379、380、381、382、383、384、385、386、387、388、389、390、391、392、393、394、395、396、397、398、399、400、401、402、403、404、405、406、407、408、409、410、411、412、413、414、415、416、417、418、419、420、421、422、423、424、425、426、427、428、429、430、431、432、433、434、435、436、437、438、439、440、441、442、443、444、445、446、447、448、449、450、451、452、453、454、455、456、457、458、459、460、461、462、463、464、465、466、467、468、469、470、471、472、473、474、475、476、477、478、479、480、481、482、483、484、485、486、487、488、489、490、491、492、493、494、495、496、497、498、499、500、 501、502、503、504、505、506、507、508、509、510、511、512、513、514、515、516、517、518、519、520、521、522、523、524、525、526、527、528、529、530、531、532、533、534、535、536、537、538、539、540、541、542、543、544、545、546、547、548、549、550、551、552、553、554、555、556、557、558、559、560、561、562、563、564、565、566、567、568、569、570、571、572、573、574、575、576、577、578、579、580、581、582、583、584、585、586、587、588、589、590、591、592、593、594、595、596、597、598、599、600、601、602、603、604、605、606、607、608、609、610、611、612、613、614、615、616、617、618、619、620、621、622、623、624、625、626、627、628、629、630、631、632、633、634、635、636、637、638、639、640、641、642、643、644、645、646、647、648、649、650、651、652、653、654、655、656、657、658、659、660、661、662、663、664、665、666、667、668、669、670、671、672、673、674、675、676、677、678、679、680、681、682、683、684、685、686、687、688、689、690、691、692、693、694、695、696、697、698、699、700、701、702、703、704、705、706、707、708、709、710、711、712、713、714、715、716、717、718、719、720、721、722、723、724、725、726、727、728、729、730、731、732、733、734、735、736、737、738、739、740、741、742、743、744、745、746、747、748、749、750、751、752、753、754、755、756、757、758、759、760、761、762、763、764、765、766、767、768、769、770、771、772、773、774、775、776、777、778、779、780、781、782、783、784、785、786、787、788、789、790、791、792、793、794、795、796、797、798、799、800、801、802、803、804、805、806、807、808、809、810、811、812、813、814、815、816、817、818、819、820、821、822、823、824、825、826、827、828、829、830、831、832、833、834、835、836、837、838、839、840、841、842、843、844、845、846、847、848、849、850、851、852、853、854、855、856、857、858、859、860、861、862、863、864、865、866、867、868、869、870、871、872、873、874、875、876、877、878、879、880、881、882、883、884、885、886、887、888、889、890、891、892、893、894、895、896、897、898、899、900、901、902、903、904、905、906、907、908、909、910、911、912、913、914、915、916、917、918、919、920、921、922、923、924、925、926、927、928、929、930、931、932、933、934、935、936、937、938、939、940、941、942、943、944、945、946、947、948、949、950、951、952、953、954、955、956、957、958、959、960、961、962、963、964、965、966、967、968、969、970、971、972、973、974、975、976、977、978、979、980、981、982、983、984、985、986、987、988、989、990、991、992、993、994、995、996、997、998、999、or 1000 (or any derivable range therein) contiguous amino acids or nucleotides.
[0277] In some embodiments, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, six, seven, eight, nine, nine, twenty, twenty-one, twenty-two, twenty-three, twenty-four, twenty-five ... 2, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117 , 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178 , 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 2 09, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239,240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288 , 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337 , 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439 The amino acid at position 6, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, or 400 is substituted with alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, or valine.
[0278] In some embodiments, a polypeptide (e.g., antibody, antibody fragment, Fab, etc.) of the disclosure comprises a CDR that is at least 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical in sequence (or any range derivable therein) to one of SEQ ID NOs: 1-2804. In some embodiments, a polypeptide comprises one, two, and / or three CDRs from one of SEQ ID NOs: 1-2804. The CDRs may be those determined by Kabat, IMGT, or Chothia. In further embodiments, the polypeptide may have CDRs with one, two, and / or three amino acid changes (e.g., one or two amino acid additions, one or two amino acid deletions, substitutions) relative to these one, two, or three CDRs. In some aspects, the polypeptide additionally or alternatively comprises a variable region that is not a CDR sequence, i.e., an amino acid sequence that is at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical or homologous to the amino acid sequence of the variable region framework.
[0279] From the amino terminus to the carboxy terminus, the CDRs are CDR1, CDR2, and CDR3. In some embodiments, a polypeptide may have a CDR with one, two, and / or three amino acid changes (e.g., one or two amino acid additions, one or two amino acid deletions, substitutions) relative to CDR1, CDR2, or CDR3. In some embodiments, the CDRs of SEQ ID NOs:1-2804 may further comprise one, two, three, four, five, or six additional amino acids at the amino- or carboxy-terminus of the CDR. The additional amino acids may be from the heavy and / or light chain framework regions of SEQ ID NOs:44-76, which are shown immediately adjacent to the CDR. Accordingly, embodiments relate to polypeptides comprising an HCDR1 (i.e., CDR-H1), HCDR2 (i.e., CDR-H2), HCDR3 (i.e., CDR-H3), LCDR1 (i.e., CDR-L1), LCDR2 (i.e., CDR-L2), and / or LCDR3 (i.e., CDR-L3) having at least 1, 2, 3, 4, 5, 6, or 7, or at most 1, 2, 3, 4, 5, 6, or 7, or exactly 1, 2, 3, 4, 5, 6, or 7 amino acids at the amino-terminus of the CDR or the carboxy-terminus of the CDR, wherein the additional amino acids are 1, 2, 3, 4, 5, 6, or 7 amino acids of Table 1 or SEQ ID NOs: 1-2804, as shown immediately adjacent to the CDR. Other embodiments relate to antibodies comprising one or more CDRs, wherein the CDR is a fragment of Table 1 or SEQ ID NOs:1-2804, and the fragment lacks 1, 2, 3, 4, or 5 amino acids from the amino or carboxy terminus of the CDR. In some embodiments, the CDR may lack 1, 2, 3, 4, 5, 6, or 7 amino acids from the carboxy terminus and may further comprise 1, 2, 3, 4, 5, 6, 7, or 8 amino acids from framework regions at the amino terminus of the CDR. In some embodiments, the CDR may lack 1, 2, 3, 4, 5, 6, or 7 amino acids from the amino terminus and may further comprise 1, 2, 3, 4, 5, 6, 7, or 8 amino acids from framework regions at the carboxy terminus of the CDR.In further embodiments, the antibody may alternatively or additionally be humanized in a region outside of the CDR(s) and / or variable region(s). In some aspects, the polypeptide additionally or alternatively comprises an amino acid sequence that is at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or 100% identical or homologous to the amino acid sequence of the variable region, i.e., the variable region framework, that is not a CDR sequence.
[0280] In other embodiments, the polypeptide or protein comprises one, two, three, four, five, or six CDRs from either or both of the light and heavy chain variable regions of Table 1 or SEQ ID NOs:1-2804, and the one, two, three, four, five, or six CDRs may have one, two, and / or three amino acid changes relative to those CDRs. In some embodiments, some or all of the antibody sequence outside the variable regions is humanized. The protein may comprise one or more polypeptides. In some aspects, the protein may contain one or two polypeptides similar to heavy chain polypeptides and / or one or two polypeptides similar to light chain polypeptides.
[0281] Nucleotide and protein, polypeptide and peptide sequences for various genes have been disclosed and can be found in recognized computerized databases.Two commonly used databases are the Genbank and GenPept databases of the National Center for Biotechnology Information (ncbi.nlm.nih.gov / on the World Wide Web) and the Universal Protein Resource (UniProt; uniprot.org on the World Wide Web).The coding regions of these genes can be amplified and / or expressed using the techniques disclosed herein or as known to those skilled in the art.
[0282] It is contemplated that there will be about 0.001 mg to about 10 mg of total polypeptide, peptide and / or protein per ml in the compositions of the present disclosure. The concentration of protein in the composition may be about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg / ml or more, or at least about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg / ml or more. It can be 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg / ml or more, or up to about 0.001, 0.010, 0.050, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0 mg / ml or more (or any range derivable therein).
[0283] VI. Arrays Embodiments of the polypeptides, antibodies and antigen-binding fragments are then shown in the table below.
[0284] Table 1. Antibody and antigen binding profiles TIFF2024500313000002.tif68150TIFF2024500313000003.tif218150TIFF2024500313000004.tif219150TIFF2024500313000005.tif221150TIFF2024500313000006.tif214150TIFF2024500313000007.tif222150TIFF2024500313000008.tif222150TIFF2024500313000009.tif218150TIFF2024500313000010.tif218150TIFF2024500313000011.tif216150TIFF2024500313000012.tif222150TIFF2024500313000013.tif218150TIFF2024500313000014.tif222150TIFF2024500313000015.tif218150TIFF2024500313000016.tif222150TIFF2024500313000017.tif219150TIFF2024500313000018.tif212150TIFF2024500313000019.tif218150TIFF2024500313000020.tif218150TIFF2024500313000021.tif220150TIFF2024500313000022.tif214150TIFF2024500313000023.tif222150TIFF2024500313000024.tif218150TIFF2024500313000025.tif219150TIFF2024500313000026.tif220150TIFF2024500313000027.tif215150TIFF2024500313000028.tif220150TIFF2024500313000029.tif219150TIFF2024500313000030.tif222150TIFF2024500313000031.tif219150TIFF2024500313000032.tif219150TIFF2024500313000033.tif216150TIFF2024500313000034.tif218150TIFF2024500313000035.tif222150TIFF2024500313000036.tif219150TIFF2024500313000037.tif220150TIFF2024500313000038.tif219150TIFF2024500313000039.tif218150TIFF2024500313000040.tif218150TIFF2024500313000041.tif220150TIFF2024500313000042.tif217150TIFF2024500313000043.tif220150TIFF2024500313000044.tif222150TIFF2024500313000045.tif221150TIFF2024500313000046.tif217150TIFF2024500313000047.tif218150TIFF2024500313000048.tif220150TIFF2024500313000049.tif218150TIFF2024500313000050.tif214150TIFF2024500313000051.tif221150TIFF2024500313000052.tif215150TIFF2024500313000053.tif218150TIFF2024500313000054.tif219150TIFF2024500313000055.tif219150TIFF2024500313000056.tif220150TIFF2024500313000057.tif212150TIFF2024500313000058.tif218150TIFF2024500313000059.tif218150TIFF2024500313000060.tif217150TIFF2024500313000061.tif218150TIFF2024500313000062.tif218150TIFF2024500313000063.tif219150TIFF2024500313000064.tif213150TIFF2024500313000065.tif219150TIFF2024500313000066.tif218150TIFF2024500313000067.tif219150TIFF2024500313000068.tif222150TIFF2024500313000069.tif222150TIFF2024500313000070.tif220150T IFF2024500313000071.tif212150TIFF2024500313000072.tif219150TIFF2024500313000073.tif222150TIFF2024500 313000074.tif219150TIFF2024500313000075.tif220150TIFF2024500313000076.tif215150TIFF2024500313000077. tif218150TIFF2024500313000078.tif218150TIFF2024500313000079.tif217150TIFF2024500313000080.tif182150.
[0285] Table 2: Nucleic acid sequences TIFF2024500313000081.tif19150TIFF2024500313000082.tif221150TIFF2024500313000083.tif221150TIFF2024500313000084.tif221150TIFF2024500313000085.tif221150TIFF2024500313000086.tif217150TIFF2024500313000087.tif221150TIFF2024500313000088.tif221150TIFF2024500313000089.tif221150TIFF2024500313000090.tif221150TIFF2024500313000091.tif221150TIFF2024500313000092.tif221150TIFF2024500313000093.tif221150TIFF2024500313000094.tif221150TIFF2024500313000095.tif221150TIFF2024500313000096.tif221150TIFF2024500313000097.tif221150TIFF2024500313000098.tif221150TIFF2024500313000099.tif221150TIFF2024500313000100.tif221150TIFF2024500313000101.tif221150TIFF2024500313000102.tif221150TIFF2024500313000103.tif221150TIFF2024500313000104.tif221150TIFF2024500313000105.tif221150TIFF2024500313000106.tif221150TIFF2024500313000107.tif221150TIFF2024500313000108.tif221150TIFF2024500313000109.tif221150TIFF2024500313000110.tif221150TIFF2024500313000111.tif221150TIFF2024500313000112.tif221150TIFF2024500313000113.tif217150TIFF2024500313000114.tif221150TIFF2024500313000115.tif217150TIFF2024500313000116.tif221150TIFF2024500313000117.tif221150TIFF2024500313000118.tif221150TIFF2024500313000119.tif217150TIFF2024500313000120.tif221150TIFF2024500313000121.tif221150TIFF2024500313000122.tif221150TIFF2024500313000123.tif221150TIFF2024500313000124.tif221150TIFF2024500313000125.tif221150TIFF2024500313000126.tif221150TIFF2024500313000127.tif221150TIFF2024500313000128.tif221150TIFF2024500313000129.tif221150TIFF2024500313000130.tif221150TIFF2024500313000131.tif221150TIFF2024500313000132.tif221150TIFF2024500313000133.tif221150TIFF2024500313000134.tif221150TIFF2024500313000135.tif126150.
[0286] (Table 3) Summary of SEQ ID NO TIFF2024500313000136.tif221124TIFF2024500313000137.tif221143TIFF2024500313000138.tif221143TIFF2024500313000139.tif221143TIFF2024500313000140.tif221143TIFF2024500313000141.tif221143TIFF2024500313000142.tif221143TIFF2024500313000143.tif22146
[0287] 1. Variant Polypeptides The following is a discussion of changing the amino acid subunits of proteins to create equivalent or even improved second-generation variant polypeptides or peptides. For example, certain amino acids can be substituted with other amino acids in a protein or polypeptide sequence, regardless of whether or not there is a significant loss of interactive binding ability with structures such as, for example, the antigen-binding region of an antibody or the binding site on a substrate molecule. Because the interactive ability and properties of a protein define the functional activity of a protein, certain amino acid substitutions can be made in a protein sequence and its corresponding DNA coding sequence to still produce a protein with similar or desired properties. Therefore, the inventors contemplate that various changes can be made in the DNA sequence of a gene encoding a protein without any significant loss of biological availability or activity.
[0288] The term "functionally equivalent codons" is used herein to refer to codons that encode the same amino acid, such as the six different codons for arginine. Also contemplated are "neutral substitutions" or "neutral mutations," which refer to changes in one or more codons that encode biologically equivalent amino acids.
[0289] The amino acid sequence variants of the present disclosure can be substitution, insertion, or deletion variants. Mutations in the polypeptides of the present disclosure can affect 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more non-adjacent or adjacent amino acids of the protein or polypeptide compared to the wild type. Variants can include amino acid sequences that are at least 50%, 60%, 70%, 80%, or 90% identical (including all values and ranges therebetween) to any sequence provided or referenced herein. The variant can contain 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more substituted amino acids.
[0290] It will also be understood that the amino acid and nucleic acid sequences may include additional residues, e.g., additional N- or C-terminal amino acids, or 5' or 3' sequences, respectively, and still be essentially identical to those shown in one of the sequences disclosed herein, so long as the sequence meets the above criteria, including maintenance of the biological protein activity to which protein expression pertains. The addition of terminal sequences particularly applies to nucleic acid sequences, e.g., which may include various non-coding sequences adjacent to either the 5' or 3' portion of the coding region.
[0291] Deletion variants typically lack one or more residues of the native or wild-type protein. Individual residues can be deleted, or several adjacent amino acids can be deleted. A stop codon can be introduced (by substitution or insertion) into the encoding nucleic acid sequence to create a truncated protein.
[0292] Insertional mutants typically involve the addition of amino acid residues at non-terminal points in a polypeptide.This can include the insertion of one or more amino acid residues.Terminal additions can also be made, and can include fusion proteins that are multimers or concatamers of one or more peptides or polypeptides described or referenced herein.
[0293] Substitution variants typically involve the exchange of one amino acid for another at one or more sites within a protein or polypeptide, which can be designed to modulate one or more properties of the polypeptide, with or without the loss of other functions or properties. Substitutions can be conservative, i.e., one amino acid is substituted with an amino acid having similar chemical properties. A "conservative amino acid substitution" can involve the exchange of a member of one amino acid class with another member of the same class. Conservative substitutions are well known in the art, and include, for example, alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartic acid to glutamic acid; cysteine to serine; glutamine to asparagine; glutamic acid to aspartic acid; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.Conservative amino acid substitutions can include non-naturally occurring amino acid residues, which are typically incorporated by chemical peptide synthesis rather than by synthesis in living systems. These include peptide mimetics or other reversed or inverted forms of amino acid moieties.
[0294] Alternatively, substitutions may be "non-conservative" such that the function or activity of the polypeptide is affected. Non-conservative changes typically involve substituting an amino acid residue with a chemically dissimilar residue, for example, substituting a polar or charged amino acid for a non-polar or uncharged amino acid, or vice versa. Non-conservative substitutions may involve exchanging a member of one amino acid class for a member from another class.
[0295] 2. Substitution Considerations Those skilled in the art can use well-known techniques to determine suitable variants of polypeptides as shown herein. Those skilled in the art can identify suitable regions of molecules that can be changed without destroying activity by targeting regions that are not believed to be important for activity. Those skilled in the art can also identify amino acid residues and portions of molecules that are conserved between similar proteins or polypeptides. In a further embodiment, regions that may be important for biological activity or structure can be subjected to conservative amino acid substitutions without significantly changing biological activity or adversely affecting protein or polypeptide structure.
[0296] When making such changes, the hydropathic index of the amino acids can be taken into consideration. The hydropathic profile of a protein is calculated by assigning a numerical value (the "hydropathy index") to each amino acid and then averaging these values repeatedly along the peptide chain. Each amino acid is assigned a value based on its hydrophobicity and charge characteristics. These are isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cysteine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (1.6); histidine (-3.2); glutamic acid (-3.5); glutamine (-3.5); aspartic acid (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5). The importance of the hydropathic amino acid index in conferring interactive biological function to a protein is generally understood in the art (Kyte et al., J. Mol. Biol. 157:105-131 (1982)). It is recognized that the relative hydropathic properties of amino acids contribute to the secondary structure of the associated protein or polypeptide, which in turn determines the interaction of the protein or polypeptide with other molecules, such as enzymes, substrates, receptors, DNA, antibodies, antigens, etc. It is also known that certain amino acids can be substituted for other amino acids having a similar hydropathic index or score and still retain similar biological activity. In making changes based on hydropathic index, certain embodiments include substitutions of amino acids whose hydropathic index is within ±2. In some aspects of the invention, within ±1 is included, and in other aspects of the invention, within ±0.5 is included.
[0297] It is also understood in the art that similar amino acid substitutions can be made effectively based on hydrophilicity. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with the biological properties of the protein. In certain embodiments, the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigen binding (i.e., as a biological property of the protein). The following hydrophilicity values have been assigned to these amino acid residues: arginine (+3.0); lysine (+3.0); aspartic acid (+3.0±1); glutamic acid (+3.0±1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5±1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); and tryptophan (-3.4). When making changes based on similar hydrophilicity values, certain embodiments include substitutions of amino acids whose hydrophilicity values are within ±2, other embodiments include those within ±1, and still other embodiments include those within ±0.5. In some cases, epitopes may be identified from a primary amino acid sequence based on hydrophilicity. These regions are also referred to as "epitope core regions." It is understood that an amino acid can be substituted for another with a similar hydrophilicity value and still produce a biologically equivalent and immunologically equivalent protein.
[0298] In addition, one skilled in the art can review structure-function studies that identify residues in similar polypeptides or proteins that are important for activity or structure. In light of such comparisons, one can predict the importance of amino acid residues in a protein that correspond to amino acid residues in the similar protein that are important for activity or structure. One skilled in the art can select chemically similar amino acid substitutions for such predicted important amino acid residues.
[0299] Those skilled in the art can also analyze the three-dimensional structure and amino acid sequence in relation to the structure of similar proteins or polypeptides. Taking such information into account, those skilled in the art can predict the alignment of the amino acid residues of an antibody relative to its three-dimensional structure. Because amino acid residues predicted to be on the surface of a protein may be involved in important interactions with other molecules, those skilled in the art can choose not to make changes to such residues. Furthermore, those skilled in the art can create test variants containing single amino acid substitutions at each desired amino acid residue. These variants can then be screened for binding and / or activity using standard assays, thereby obtaining information gathered from such routine experiments, allowing those skilled in the art to determine which amino acid positions should be avoided for further substitutions, either alone or in combination with other mutations. Various tools available for determining secondary structure can be found on the World Wide Web at expasy.org / proteomics / protein_structure.
[0300] In some embodiments of the present invention, amino acid substitutions are made that (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for protein complex formation, (4) alter ligand or antigen binding affinity, and / or (5) confer or modify other physicochemical or functional properties to such polypeptides. For example, single or multiple amino acid substitutions (in certain embodiments, conservative amino acid substitutions) may be made in a naturally occurring sequence. Substitutions may be made in portions of an antibody outside the domain(s) that form intermolecular contacts. In such embodiments, conservative amino acid substitutions that do not substantially alter the structural features of the protein or polypeptide may be used (e.g., one or more substituted amino acids that do not disrupt the secondary structure that characterizes a native antibody).
[0301] VII. Nucleic acids In certain embodiments, nucleic acid sequences can exist in various forms, such as isolated segments of integrated sequences or recombinant polynucleotides and recombinant vectors encoding the peptides and polypeptides of the present disclosure, or fragments, derivatives, muteins, or variants thereof; polynucleotides sufficient for use as hybridization probes, PCR primers, or sequencing primers for identifying, analyzing, mutating, or amplifying polynucleotides encoding polypeptides; antisense nucleic acids for suppressing expression of polynucleotides; and complementary sequences of the foregoing described herein. Nucleic acids encoding fusion proteins containing these peptides are also provided. Nucleic acids can be single-stranded or double-stranded and can include RNA and / or DNA nucleotides, as well as artificial variants thereof (e.g., peptide nucleic acids).
[0302] The term "polynucleotide" refers to a nucleic acid molecule that is recombinant or isolated from total genomic nucleic acid. The term "polynucleotide" includes oligonucleotides (nucleic acids of 100 residues or less in length) and recombinant vectors (including, for example, plasmids, cosmids, phages, viruses, etc.). A polynucleotide, in certain aspects, includes a regulatory sequence that is substantially isolated from a naturally occurring gene or protein-coding sequence. A polynucleotide may be single-stranded (coding or antisense) or double-stranded and may be RNA, DNA (genomic, cDNA, or synthetic), analogs thereof, or combinations thereof. Additional coding or non-coding sequences may, but need not, be present within a polynucleotide.
[0303] In this regard, the terms "gene," "polynucleotide," or "nucleic acid" are used to refer to a nucleic acid (including any sequences required for proper transcription, post-translational modification, or localization) that encodes a protein, polypeptide, or peptide. As will be understood by those skilled in the art, this term encompasses genomic sequences, expression cassettes, cDNA sequences, and smaller engineered nucleic acid segments that express or can be adapted to express proteins, polypeptides, domains, peptides, fusion proteins, and variants. A nucleic acid encoding all or a portion of a polypeptide may contain a contiguous nucleic acid sequence that encodes all or a portion of such a polypeptide. It is also contemplated that a particular polypeptide may be encoded by a nucleic acid that contains variations having slightly different nucleic acid sequences but still encodes the same or substantially similar protein.
[0304] In certain embodiments, polynucleotide variants have substantial identity to the sequences disclosed herein; polynucleotide variants comprise at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or higher sequence identity (including all values and ranges therebetween) compared to the polynucleotide sequences provided herein using the methods described herein (e.g., BLAST analysis using standard parameters). In certain aspects, the isolated polynucleotide comprises a nucleotide sequence encoding a polypeptide having at least 90%, preferably 95% or more identity to the amino acid sequence described herein over the entire length of the sequence; or a nucleotide sequence complementary to the isolated polynucleotide.
[0305] Regardless of the length of the coding sequence itself, nucleic acid segments may be combined with other nucleic acid sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, etc., such that their overall length may vary significantly. Nucleic acids can be of any length. They can be, for example, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 75, 100, 125, 175, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1500, 3000, 5000 or more nucleotides in length, and / or can include one or more additional sequences, e.g., regulatory sequences, and / or can be part of a larger nucleic acid, e.g., a vector. Thus, it is contemplated that nucleic acid fragments of almost any length can be used, although the total length is preferably limited by the ease of preparation and use in the intended recombinant nucleic acid protocol. In some cases, the nucleic acid sequence may encode a polypeptide sequence with additional heterologous coding sequences, for example, to allow for purification, transport, secretion, post-translational modification of the polypeptide, or for therapeutic benefits such as targeting or efficacy. As discussed above, tags or other heterologous polypeptides may be added to the sequence encoding the modified polypeptide, where "heterologous" refers to a polypeptide that is not the same as the modified polypeptide.
[0306] A. Hybridization Nucleic acids hybridize to other nucleic acids under specific hybridization conditions. Methods for hybridizing nucleic acids are well known in the art. For example, see Current Protocols in Molecular Biology, John Wiley and Sons, NY (1989), 6.3.1-6.3.6. As defined herein, moderately stringent hybridization conditions use a pre-washing solution containing 5x sodium chloride / sodium citrate (SSC), 0.5% SDS, 1.0 mM EDTA (pH 8.0), a hybridization buffer of about 50% formamide, 6x SSC, and a hybridization temperature of 55°C (or other similar hybridization solutions, such as those containing about 50% formamide, a hybridization temperature of 42°C), and a washing condition of 60°C in 0.5x SSC, 0.1% SDS. Stringent hybridization conditions involve hybridization in 6×SSC at 45° C., followed by one or more washes in 0.1×SSC, 0.2% SDS at 68° C. Moreover, one skilled in the art can manipulate the hybridization and / or wash conditions to increase or decrease the stringency of hybridization so that nucleic acids containing nucleotide sequences that are at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to each other will typically remain hybridized to each other.
[0307] Parameters influencing the selection of hybridization conditions and guidance for devising suitable conditions are provided, for example, by Sambrook, Fritsch, and Maniatis (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11 (1989); Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley and Sons, Inc., sections 2.10 and 6.3-6.4 (1995) (both of which are incorporated by reference in their entireties for all purposes) and can be readily determined by one of skill in the art based, for example, on the length and / or base composition of the DNA.
[0308] B. Mutation Changes can be introduced into a nucleic acid by mutation, thereby resulting in changes in the amino acid sequence of the polypeptide (e.g., antigenic peptide or polypeptide) that it encodes. Mutations can be introduced using any technique known in the art. In one embodiment, one or more specific amino acid residues are altered, for example, using a site-directed mutagenesis protocol. In another embodiment, one or more randomly selected residues are altered, for example, using a random mutagenesis protocol. Regardless of how the mutations are made, the mutant polypeptides can be expressed and screened for desired properties.
[0309] Mutations can be introduced into nucleic acids without significantly altering the biological activity of the encoded polypeptide. For example, nucleotide substitutions can be made to result in amino acid substitutions at non-essential amino acid residues. Alternatively, one or more mutations can be introduced into nucleic acids to selectively alter the biological activity of the polypeptide it encodes. See, for example, Romain Studer et al., Biochem. J. 449:581-594 (2013). For example, mutations can quantitatively or qualitatively alter biological activity. Examples of quantitative changes include increasing, reducing, or eliminating activity. Examples of qualitative changes include changing the antigen specificity of an antibody.
[0310] C. Probe In another aspect, the nucleic acid molecule is suitable for use as a primer or hybridization probe for the detection of a nucleic acid sequence. The nucleic acid molecule can comprise only a portion of a nucleic acid sequence encoding a full-length polypeptide, for example, a fragment that can be used as a probe or primer or a fragment that encodes an active portion of a given polypeptide.
[0311] In another embodiment, the nucleic acid molecule can be used as a probe or PCR primer for a specific nucleic acid sequence. For example, a nucleic acid molecule probe can be used in diagnostic methods, or a nucleic acid molecule PCR primer can be used to amplify a region of DNA, which can be used to isolate a nucleic acid sequence for use in producing the engineered cells of the present disclosure. In a preferred embodiment, the nucleic acid molecule is an oligonucleotide.
[0312] A probe based on the desired sequence of the nucleic acid can be used to detect the nucleic acid or a similar nucleic acid, for example, a transcript encoding a polypeptide of interest. The probe can contain a label group, for example, a radioisotope, a fluorescent compound, an enzyme, or an enzyme cofactor. Such a probe can be used to identify cells expressing the polypeptide.
[0313] VIII. Polypeptide Expression In some aspects, there is a nucleic acid molecule that encodes the polypeptide, antibody or antigen-binding fragment of the present disclosure.The nucleic acid molecule can be used to express a large amount of polypeptide.If the nucleic acid molecule is derived from a non-human non-transgenic animal, the nucleic acid molecule can be used to humanize antibody or TCR gene.
[0314] A. Vector In some aspects, expression vectors containing nucleic acid molecules encoding a polypeptide of a desired sequence or a portion thereof (e.g., a fragment containing one or more CDRs or one or more variable region domains) are contemplated. Expression vectors containing nucleic acid molecules may encode heavy chains, light chains, or antigen-binding portions thereof. In some aspects, expression vectors containing nucleic acid molecules may encode fusion proteins, modified antibodies, antibody heavy and / or light chains, antibody fragments, and probes thereof. In addition to control sequences governing transcription and translation, vectors and expression vectors may further contain nucleic acid sequences that perform other functions.
[0315] To express the polypeptide or peptide of the present disclosure, DNA encoding the polypeptide or peptide is inserted into an expression vector so that the gene region is operably linked to transcriptional and translational control sequences. In some aspects, the vector encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered to allow any VH or VL sequence to be easily inserted and expressed. In some aspects, the vector encodes a functionally complete human TCR alpha or TCR beta sequence, with appropriate restriction sites engineered to allow any variable sequence or CDR1, CDR2, and / or CDR3 to be easily inserted and expressed. Typically, expression vectors used in any host cell contain sequences for plasmid or virus maintenance and sequences for cloning and expressing exogenous nucleotide sequences. Such sequences, collectively referred to as "flanking sequences," typically include one or more of the following operably linked nucleotide sequences: a promoter, one or more enhancer sequences, an origin of replication, a transcription termination sequence, a complete intron sequence containing donor and acceptor splice sites, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a polylinker region for insertion of a nucleic acid encoding a polypeptide to be expressed, and a selectable marker element. Such sequences and methods for their use are well known in the art.
[0316] B. Expression Systems Numerous expression systems exist that contain at least some or all of the expression vectors discussed above. Prokaryotic and / o...
Claims
1. An antibody or antigen-binding fragment that specifically binds to the spike protein.
2. the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region; (a) the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:561-563, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:570-572; (b) the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:435-437, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:444-446; (c) the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, each comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1191-1193, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, each comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1200-1202; (d) the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, each comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1227-1229, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, each comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1236-1238; (e) the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1425-1427, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1434-1436; (f) the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1479-1481, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:1488-1490; or (g) the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1497-1499, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3, each of which comprises an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 1506-1508; The antibody or antigen-binding fragment of claim 1.
3. The antibody or antigen-binding fragment of claim 1 or 2, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 each comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 561-563, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3 each comprising an amino acid sequence having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 570-572.
4. The antibody or antigen-binding fragment of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 that have at least 80% sequence identity to HCDR1, HCDR2, and HCDR3 from the heavy chain variable region of the antibody clone in Table 1, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3 that have at least 80% sequence identity to LCDR1, LCDR2, and LCDR3 from the light chain variable region of the same antibody clone in Table 1.
5. the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region; (a) the heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 having the amino acid sequences of HCDR1, HCDR2, and HCDR3 of a clone in Table 1, and the light chain variable region comprises LCDR1, LCDR2, and LCDR3 that comprise the amino acid sequences of LCDR1, LCDR2, and LCDR3 from the light chain variable region of the same clone in Table 1; and / or (b)(i) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 each comprise an amino acid sequence having at least 80% sequence identity to HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 in Table 1, and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are from the same antibody clone; or (ii) HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 in Table 1, respectively, and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are from the same antibody clone; and / or (c) the heavy chain variable region comprises an amino acid sequence having at least 80% sequence identity to the heavy chain variable region of the antibody clone of Table 1, and / or the light chain variable region comprises an amino acid sequence having at least 80% sequence identity to the light chain variable region of the same antibody clone of Table 1, optionally wherein the heavy chain variable region comprises the amino acid sequence of the heavy chain variable region of the antibody clone of Table 1, and / or the light chain variable region comprises the amino acid sequence of the same antibody clone of Table 1; and / or (d)(i) the antibody or antigen-binding fragment comprises heavy chain framework regions (HFR) 1, HFR2, HFR3, and HFR4, and light chain framework regions (LFR) 1, LFR2, LFR3, and LFR4, wherein HFR1, HFR2, HFR3, and HFR4 comprise amino acid sequences having at least 80% sequence identity to HFR1, HFR2, HFR3, and HFR4, respectively, of the antibody clone of Table 1, and LFR1, LFR2, LFR3, and LFR4 comprise amino acid sequences having at least 80% sequence identity to LFR1, LFR2, LFR3, and LFR4, respectively, of the same antibody clone of Table 1; or (ii) HFR1, HFR2, HFR3, and HFR4 comprise the amino acid sequences of HFR1, HFR2, HFR3, and HFR4, respectively, of the antibody clones of Table 1, and LFR1, LFR2, LFR3, and LFR4 comprise the amino acid sequences of LFR1, LFR2, LFR3, and LFR4, respectively, of the same antibody clones of Table 1; and / or (e) the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence having at least 70% sequence identity to the heavy chain of the antibody clone of Table 1, and the light chain comprises an amino acid sequence having at least 70% sequence identity to the light chain of the same antibody clone of Table 1, optionally, the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises an amino acid sequence of the antibody clone of Table 1, and the light chain comprises an amino acid sequence of the same antibody clone of Table 1; and / or (f) the antibody is a human, chimeric, or humanized antibody; and / or (g) the antibody or antigen-binding fragment binds to a SARS-CoV-2 protein in a concentration of about 10 -6 nM to about 10 -12 pM K D and / or (h) the antibody is a neutralizing antibody; and / or (i) the antibody is a human antibody, a humanized antibody, a recombinant antibody, a chimeric antibody, an antibody derivative, a veneered antibody, a diabody, a monoclonal antibody, a single domain antibody, or a single chain antibody; or (ii) The antigen-binding fragment is a single-chain variable fragment (scFv), F(ab') 2 , Fab', Fab, Fv, or rIgG; The antibody or antigen-binding fragment of claims 1 to 4.
6. A polypeptide comprising the antigen-binding fragment of any one of claims 1 to 5, optionally comprising: (a) the polypeptide comprises at least two antigen-binding fragments, each antigen-binding fragment being independently selected from the antigen-binding fragment of any one of claims 1 to 5; and / or (b) the polypeptide is multivalent; and / or (c) the polypeptide is bispecific; The polypeptide.
7. A composition comprising the antibody or antigen-binding fragment of any one of claims 1 to 5.
8. (a) containing a pharmaceutical excipient; and / or (b) further comprising an adjuvant; and / or (c) formulated for parenteral, intravenous, subcutaneous, intramuscular, or intranasal administration; and / or (d) comprises at least two antibodies or antigen-binding fragments; The composition of claim 7.
9. One or more nucleic acids encoding the antibody or antigen-binding fragment of any one of claims 1 to 5 or the polypeptide of claim 6(c).
10. (a) an antibody heavy chain, the nucleic acid having at least 70% sequence identity to one of SEQ ID NOs: 1621-1710 or 2707-2755; or (b) an antibody light chain, the nucleic acid having at least 70% sequence identity to one of SEQ ID NOs: 1711-1800 or 2756-2804; A nucleic acid encoding
11. A vector comprising the nucleic acid of claim 9 or 10.
12. A host cell comprising a nucleic acid according to claim 9 or 10 or a vector according to claim 11, the host cell being optionally a human cell, a B cell, a T cell, a Chinese hamster ovary, an NS0 mouse myeloma cell, or a PER.C6 cell.
13. A method for producing a cell, comprising the step of introducing a nucleic acid according to claim 9 or 10 or a vector according to claim 11 into a cell, optionally comprising: (a) further comprising the step of culturing said cell under conditions that allow expression of a polypeptide from said nucleic acid, and optionally further comprising the step of isolating the expressed polypeptide; and / or (b) the cell is a human cell, a B cell, a T cell, a Chinese hamster ovary cell, an NS0 mouse myeloma cell, or a PER.C6 cell; The method.
14. 13. A method for producing a polypeptide comprising the steps of: introducing a nucleic acid according to claim 9 or 10 or a vector according to claim 11 into a cell; and isolating the polypeptide expressed from the nucleic acid, optionally wherein the cell is a human cell, a B cell, a T cell, a Chinese hamster ovary, an NS0 mouse myeloma cell, or a PER.C6 cell.
15. A pharmaceutical composition comprising the antibody or antigen-binding fragment of any one of claims 1 to 5, the polypeptide of claim 6, or the host cell of claim 12, for treating or preventing a coronavirus infection in a subject.
16. (a) the subject is a human subject; and / or (b) (i) whether the coronavirus infection is SARS-CoV-2; (ii) the subject has one or more symptoms of coronavirus infection; or (iii) the subject does not have any symptoms of coronavirus infection; and / or (c)(i) the subject has been diagnosed with coronavirus infection; or (ii) the subject has not been diagnosed with coronavirus infection; and / or (d)(i) Whether the subject has previously been vaccinated against a coronavirus; (ii) the subject has not been previously vaccinated against a coronavirus, or (iii) the subject has previously been treated for a coronavirus infection; and / or (e) the antibody, antigen-binding fragment, polypeptide, or cell is administered by parenteral, intravenous, subcutaneous, intramuscular, or intranasal administration; and / or (f) in combination with an additional therapy, optionally where the additional therapy comprises a steroid or an antiviral therapy, and further optionally where the additional therapy comprises dexamethasone or remdesivir; 16. The pharmaceutical composition of claim 15.
17. A method for evaluating a sample from a subject, comprising contacting a biological sample or an extract thereof from the subject with at least one antibody or antigen-binding fragment of any one of claims 1 to 5 or a polypeptide of claim 6.
18. A method for testing for SARS-CoV-2 infection in a subject, comprising contacting a biological sample or an extract thereof from the subject with at least one antibody or antigen-binding fragment of any one of claims 1 to 5 or a polypeptide of claim 6.
19. (a) the at least one antibody, antigen-binding fragment, or polypeptide is operably linked to a detectable label; and / or (b) the method further comprises the step of incubating the antibody, antigen-binding fragment, or polypeptide under conditions that allow binding of the antibody, antigen-binding fragment, or polypeptide to an antigen in the biological sample or extract thereof; and / or (c) the method further comprises detecting binding of an antigen to the antibody, antigen-binding fragment, or polypeptide; and / or (d) the method further comprises contacting the biological sample with at least one capture antibody, antigen, or polypeptide, and optionally (i) the at least one capture antibody, antigen-binding fragment, or polypeptide comprises at least one antibody according to any one of claims 1 to 6; and / or (ii) the capture antibody is linked to a solid support; and / or (e) the biological sample comprises a blood sample, a urine sample, a stool sample, or a nasopharyngeal sample; 19. The method of claim 17 or 18.
